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Summary  
Autoimmune polyendocrine syndrome type I (APS-I) is a rare, monogenetic 
recessively inherited disease caused by mutations in the autoimmune regulator 
(AIRE) gene. The patients display different endocrine and ectodermal manifestations, 
where the majority develop at least two of the three main components of autoimmune 
adrenocortical failure (Addison’s disease), hypoparathyroidism and chronic 
mucocutaneous candidiasis (CMC). In addition, patients frequently develop 
autoantibodies against molecular targets in their affected organs and against cytokines 
of the immune system. 
 
In two studies, robust immunoassays detecting APS-I patients with high sensitivity 
and specificity were developed. Autoantibodies against in vitro transcribed and 
translated interferon omega (IFN-) and interleukin (IL) 17F and IL-22 were 
measured, the latter shown to correlate to CMC. Antibodies against IFN- were 
confirmed as a universal marker for APS-I, suggesting this assay as an ideal 
screening tool preceding mutational analyses in suspected APS-I cases. We have 
shown that single nucleotide polymorphisms and variation in copy number of AIRE 
have no association with Addison’s disease. However, large deletions in one allele of 
AIRE together with a concomitant disease-causing mutation were discovered in two 
APS-I patients, underpinning the importance of copy number analysis. A wide range 
of immune cell subsets were studied, identifying disturbances in the regulatory T cell 
compartment together with less CCR6+CXCR3+ T cells and a reduction in CD16+ 
monocytes in patients with APS-I, possibly resulting in susceptibility for developing 
autoimmune manifestations.  
 
The characterisation of genetic variations in AIRE and of abnormalities in the 
immune cell subsets contribute to our understanding of the function of AIRE, while 
establishing immunoassays ease the identification of APS-I patients.  
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17-OH  steroid cytochrome P450 17-alpha-hydroxylase 
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AHR   aryl hydrocarbon receptor 
AIRE   autoimmune regulator 
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ELISA  enzyme-linked immunosorbent assay  
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FOXP3  forkhead box P3 
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HLA   human leukocyte antigen 
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IFN   interferon 
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IL   interleukin 
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JNK   c-Jun N-terminal kinase 
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MAPK  mitogen-activated protein kinase 
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OMIM  online Mendelian inheritance in men 
PAMP  pathogen-associated molecular pattern 
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PHD   plant homeodomain zinc finger 
PLZF   promyelocytic leukemia zink finger 
PRRs   pattern recognition receptor 
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Introduction 
A functioning immune system is a necessity for survival as it provides protection 
from a wide array of bacteria, viruses and fungi that we encounter in our daily lives. 
If the physical barriers of the skin and mucosal membranes are breached, invading 
pathogens are cleared by the innate and adaptive immune responses, which include a 
broad range of signalling and effector proteins, and different cell-types. This is a 
process demanding strict control, to assure clearance of foreign agents without 
causing tissue damage. In some instances this control fails and the immune cells 
become autoreactive, resulting in an autoimmune disease [1]. 
 
Autoimmune diseases are caused by the combined effects of multiple susceptibility 
genes, environmental triggers and stochastic events. However, a few monogenic 
autoimmune diseases exist, which constitute powerful models. Among them, 
autoimmune polyendocrine syndrome type I (APS-I) has thought us how central 
tolerance is developed. In the following, a brief introduction to the immune system 
and autoimmunity is given, with particular emphasis on APS-I and its underlying 
autoimmune regulator (AIRE) gene.  
 
Innate immunity 
The innate immune reactions are mediated by cells like dendritic cells (DCs), 
macrophages, neutrophils and natural killer cells, in combination with circulating 
proteins of the complement system, and anti-microbial peptides [2, 3]. This 
immediate response utilises a limited number of germ-line encoded pattern 
recognition receptors (PRRs) which detect pathogen-associated molecular patterns 
(PAMPs) found in most microorganisms [4]. The best characterised PRRs is the Toll-
like receptors (TLRs), which trigger activation of adaptive immune responses and 
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control them at multiple levels, e.g. the induction of T helper (Th) 1 cells, production 
of immunoglobulins (Igs) by B cells, and activation of cytotoxic T cells (Tc) [5]. 
 
Adaptive immunity 
The adaptive immune system depends on randomly generated receptors clonally 
displayed on the membranes of T and B cells in order to fight down infection. These 
receptors have infinite specificity in their recognition of antigen, and although the 
adaptive immune system acts slower than the innate branch, it inhabits 
immunological memory [6].  
 
B cells 
When the B cell receptor (BCR) encounters its specific antigen in its native form, 
usually in the presence of cytokines provided by Th cells, the B cells shift to clonal 
expansion. Clones with identical receptor specificity are then produced; most will 
develop into plasma cells and produce large amounts of Igs while some develop into 
memory cells that can be rapidly reactivated on the next encounter with the antigen. 
The secreted Igs are quite similar to the BCR, only without a transmembrane region. 
The different isotypes have different effector functions and are named by their 
constant region as IgA, IgD, IgG, IgM, and IgE, and bind soluble antigens by their 
variable domains. Destruction of the pathogen by interaction with the secreted Igs 
either leads to neutralisation of the pathogen, marks it for opsonisation, or activates 
the complement system. In addition to the production of Igs, B cells up-regulate co-
stimulatory molecules, they express antimicrobial activity and secrete factors directly 
mediating microbial destruction, in addition to act as antigen presenting cells (APC) 
for T cells [7]. 
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Failure of establishing B cell tolerance in the bone marrow [8-12] or in the outer T 
cell zones of the spleen where the antibody response to foreign antigens is initiated, 
may result in autoreactive B cells and the production of autoantibodies [13, 14]. 
These autoreactive B cells are thought of as important APCs for T cells in the 
initiation and development of an immune response toward self-antigens driven by 
cluster of differentiation (CD)4+ cells [15, 16], and may promote autoimmunity by 
multiple pathways and mechanisms [17].  
 
T cells 
The heterogeneous group of T cells play a central role in cell-mediated immunity. 
They commit to linages specified by their surface markers, as single positive (SP) 
CD8 or CD4 expressing T cells. These surface markers direct their interaction with 
the major histocompability cluster of genes (MHC), where CD8 are specific for MHC 
class I expressed on all nucleated cells, and CD4 for MHC class II, expressed on B-
cells, dendritic cells and activated macrophages. The CD8+ Tc killer cells eliminate 
infected cells of the body, which display peptides of their invading agent on MHC 
class I. The cytokine-secreting CD4+ Th cells diverge into different subset, a 
paradigm established by the discovery of the distinct Th1 and Th2 subsets in mice in 
1986 [18]. The differentiation of a naïve CD4+ T cells into the different groups of (i) 
proinflammatory effector (Th) cells or (ii) regulatory T (Treg) cells depend on the 
cytokine milieu influenced by the innate immune system and type of invading 
organism, together with the strength and duration of the interaction between the T 
cell and the APC [19]. Different transcription factors characterise each Th cell subset 
and drive the expression of distinct soluble mediators and surface molecules in 
response to a specific microbe, to initiate clearance of the pathogen and tissue 
inflammation (Fig. 1). This initial proinflammatory response by the Th cells is 
followed by an activation of the Treg cells, which dampen the immune response to 
limit collateral tissue damage [20-22].  
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Figure 1. Overview of the CD4+ T cell differentiation. The T cell-subsets that will be emphasised here are 
highlighted, including their specific transcription factors, and some of their secreted effector molecules. Upon 
interaction with an APC, the naïve CD4+ cells separate into different subsets due to their developmental 
programs, dependent on the cytokine environment. Each subset is characterised by expression of cytokines that 
regulate other immune cells. Commitment to the Th1 linage is promoted by interleukin (IL) 12 and the type I 
interferons (IFNs) in humans [23] to activate their signature transcription factor T-bet (T-box transcription factor) 
[24]. The Th1 cells produce the proinflammatory cytokine IFN-gamma (IFN-) to aid the clearance of viruses and 
intracellular bacteria, in immune reactions that may cause tissue damage [25]. The Th17 cells are mainly 
promoted by tumor growth factor (TGF)  and IL-6 [26, 27], and are dependent on the transcription factor RAR-
related orphan receptor C gamma (RORt) [28] to express IL-17A, IL17-F, IL-22 and IL-26. They are responsible 
for the clearance of extracellular bacteria and fungi, especially at mucosal surfaces. The Th22 subset is 
promoted by IL-6 and tumor necrosis factor (TNF)  to produce IL-22 and is dependent on the transcription 
factor aryl hydrocarbon receptor (AHR) [29-31]. The Tregs are recognised by surface expression profile 
consisting of CD25, CD62L and specific CD45 isoforms [32-34] and their transcription factor forkhead box P3 
(FOXP3). They regulate the immune homeostasis and control unwanted immune responses [35-37]. 
Subpopulations include the functionally similar iTregs, which are induced in the periphery, and the natural 
nTregs, generated in thymus. The nTregs are regarded as stable, while the iTreg are induced by TGF-, 
thereby sharing a signal of differentiation with Th17, establishing a balance between the proinflammatory and 
anti-inflammatory cell subsets. It is still unclear how to separate nTreg from iTreg cells, as are any differences in 
biological functions. NKT (natural killer T) cells have a restricted TCR-repertoire, and inhabit an activated, 
memory cell phenotype, possibly dependent on the transcriptional regulator promyelocytic leukemia zinc finger 
(PLZF) for their development [38, 39].  
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Autoimmune diseases 
Autoimmune diseases include a wide range of conditions, differing in severity and 
symptoms. In the developed world, they affect five to ten per cent of the population 
[40]. Almost every endocrine organ is a potential target for an autoimmune attack, 
and several may be targeted at the same time as part of a polyendocrine syndrome. 
The most common endocriopathies include Hashimoto’s thyroiditis, Graves’ disease 
and type 1 diabetes [41], and their pathogenesis and etiology are still obscure, but 
most are thought to result from a combination of environmental and genetic factors. 
The last decades have brought an increase in the incidence of type 1 diabetes [42, 43], 
possibly due to the relative reduction in childhood infections and the development of 
extensive immunisation programs, proposed as the “hygiene hypothesis” [44]. The 
human leukocyte antigen (HLA) genes are among the most important genetic risk 
factors, where distinct genotypes predispose for different autoimmune diseases. Yet, 
the exact polymorphisms that confer risk are hard to elucidate due to the extensive 
linkage disequilibrium (LD) in the HLA region [45]. A few monogenic autoimmune 
diseases, such as APS-I and immunodysregulation polyendocrinopathy enteropathy 
X-linked syndrome (IPEX), have been especially powerful models in studies of the 
immune system and how it fails in autoimmunity.  
  
Autoimmune polyendocrine syndrome type I 
APS-I (online mendelian inheritance in man (OMIM) 240300), also known as 
APECED (autoimmune polyendocrinopathy-candidiasis ectodermal dystrophy), is a 
monogenic, autoimmune disease leading to several endocrine and ectodermal 
manifestations as well as to chronic mucocutaneous candidiasis (CMC). The disease 
is rare (about 1: 90 000 in Norway [46]), but more common in certain populations 
such as the Finnish (1:25 000), Sardinian (1:14 000) and among Iranian Jews (1: 
9000) [47]. The disease typically presents early in childhood, but the patients 
gradually develop autoimmune manifestations throughout life. 
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Diagnosis 
Clinical diagnosis is based on the presence of two of the three main components; 
CMC, primary hypoparathyroidism and autoimmune adrenocortical insufficiency 
(Addison’s disease). Patients often suffer from other manifestations, like primary 
ovarian failure, chronic diarrhoea and malabsorption, keratitis, autoimmune hepatitis, 
vitiligo, alopecia and enamel hypoplasia (Fig. 2) [47-49]. One of the three major 
components is sufficient for diagnosis if a sibling already is identified with APS-I, or 
if a mutation is found in both alleles on AIRE. APS-I should be suspected if one of 
the three major components present before the age of thirty, together with at least one 
of the other components [50].  
 
Left undiagnosed and untreated, APS-I may have a fatal outcome. In 1962, sixteen 
out of twenty-three (69.5%) patients died before the age of thirty [51], while this 
number decreased to four out of forty-one (10%) in a patient group followed from 
1967 to 1996 [47]. Early diagnosis, close monitoring of new disease-components and 
suitable treatment are therefore essential for this group of patients, making the need 
for good diagnostic assays and awareness among the general physicians of outmost 
importance.  
 
  
 
Figure 2. Illustration of the different manifestations in patients suffering from APS-I. 
Adrenocortical insufficiency, hypoparathyroidism and chronic mucocutaneous candidiasis are the 
three main symptoms of APS-I, and a wide array of different additional manifestations are usually 
present. Reproduced with permission from Husebye et al. Journal of Internal Medicine, 2009 [50] 
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The major components 
Chronic mucocutaneous candidiasis 
CMC is often the first sign of APS-I, presenting in the first years of life as Candida 
Albicans infections of nails, skin, and the mucous membranes in the mouth, 
oesophagus and vagina. From a study of the Finnish patients, one in six was 
diagnosed with CMC by the age of one, which increased to ninety-eight per cent by 
the age of thirty [49], and corresponding numbers are found among the Norwegian 
patients [46]. The infections differ in severity between the patients, but are often 
recurrent and difficult to treat. Prolonged oral CMC may increase the risk of 
squamous cell carcinoma, and it is therefore important with proper and antifungal 
treatment [52]. 
  
Hypoparathyroidism 
Hypoparathyroidism is the second most prevalent feature of APS-I, and typically 
presents in eighty-five per cent of the patients by the age of thirty [49], which is also 
representative for the Norwegian cohort regardless of age [53]. This is usually the 
first endocrine manifestation, and is more prevalent in women than in men [54]. 
Hypoparathyroidism is caused by autoimmune destruction of the parathyroid glands 
which decrease plasma calcium leading to paraesthesias and cramps. It is treated with 
vitamin D analogues and calcium and magnesium supplementation, but is the most 
challenging APS-I disease-component to manage [50]. The immunological target 
within the parathyroid cells is the NACHT leucine-reich repeat protein 5 (NALP5), 
and autoantibodies against NALP5 are correlated to hypoparathyroidism [55].  
 
Adrenal insufficiency 
Autoimmune Addison’s disease (AAD) typically appears after CMC and 
hypoparathyroidism, as the third most common feature in APS-I, with a seventy-eight 
per cent prevalence among the Finnish patients by the age of thirty [49]. In a 
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Norwegian survey, eighty per cent of the cohort had this manifestation, regardless of 
age [53]. Addison’s disease was first described by Thomas Addison in 1855 [56], and 
is characterised by fatigue, salt craving, weight loss and increased pigmentation of the 
skin and mucus membranes. The first serological sign of AAD is autoantibodies 
against 21-hydroxylase (21-OH) which can present up to years before any 
biochemical and clinical evidence of adrenal insufficiency [57, 58]. Early diagnosis is 
important, as untreated AAD is fatal [59]. Replacement therapy with hydrocortisone 
and fludrocortisone largely normalises mortality rates [60]. 
 
The Norwegian registry of organ-specific autoimmune diseases  
In 1996 the Norwegian registry of organ-specific autoimmune diseases (ROAS) was 
established, gathering information from patients with endocrine autoimmune 
diseases, particularly APS-I and Addison’s disease. ROAS contains information on 
disease components, current treatment, autoantibody profiles, and allelic variations of 
several genes. The biobank includes blood, sera, DNA, peripheral blood mononuclear 
cells, tears, and saliva regularly sampled from the patients. Both the characterisation 
and the collection of biological material from the Norwegian APS-I patients is on-
going work. To date, ROAS includes 39 APS-I patients. In addition, records of 11 
diseased patients have been collected. The registry and the corresponding bio-bank 
have been approved by the Norwegian data directorate and regional ethical 
committee. 
 
Autoantibodies in APS-I 
Organ-specific autoantibodies in APS-I 
Due to their deficiency in developing tolerance to self, B cells and plasma cells from 
patients suffering from APS-I typically produce a variety of autoantibodies directed 
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against intracellular enzymes in the affected organs (Table 1). These organ-specific 
autoantibodies have proven to be excellent markers for autoimmune disease in the 
organ which they are expressed. Since they often precede clinical symptoms, they are 
assayed at routine basis in this group of patients [47, 61, 62]. 
  
Table 1. Common organ-specific autoantigens in APS-I, their main organ of expression relevant to 
APS-I, associated disease components and reported prevalence. 
Autoantigen Main expression Disease component Prevalence (%)* Ref. 
21-OH Adrenal cortex Addison’s disease 66 [58, 63-65] 
SCC Adrenal cortex, gonads 
Addison’s disease, 
hypogonadism 52 [64-66] 
17-OH Adrenal cortex, gonads 
Addison’s disease, 
hypogonadism 44 
[64, 65, 
67] 
GAD65 Pancreas Intestinal dysfunction 37 [57, 68] 
CYP1A2 Liver Autoimmune hepatitis 8 [69] 
AADC Pancreas, liver Hepatitis, Vitiligo 51 [70] 
TPH Duodenum Malabsorption 45 [71] 
TH Keratinocytes Alopecia 40 [72] 
NALP5 Parathyroid gland, 
ovary Hypoparathyriodism 41** [55] 
21OH; 21-Hydroxylase, SCC; Side-chain cleavage enzyme, 17-OH; 17--Hydroxylase, GAD; Glutamic acid 
decarboxylase, CYP1A2; Cytochrome P450 1A2, AADC; Aromatic L-amino acid decarboxylase, TPH; 
Tryptophan hydroxylase, TH; Tyrosine hydroxylase, NALP5; NACHT leucine-reich repeat protein 5 
*Prevalence is based on detected autoantibodies in a cohort of Finnish, Swedish and Norwegian APS-I patients, 
n=90 [57].  
**Prevalence is based on detected autoantibodies in a cohort of Finnish, Swedish and Norwegian APS-I patients, 
n=87 [55]. 
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The adrenal, steroidogenic P450 superfamily autoantigens 21-OH, 17--hydroxylase 
(17-OH), and side-chain cleavage enzyme (SCC) catalyse chemical reactions required 
for the production of steroid hormones, like aldosterone and cortisol (21-OH), 
progesterone (17-OH), and pregnenolone (SCC) [58, 65, 67, 73]. Assay of 
autoantibodies against 21-OH is an excellent marker for Addison’s disease, both in its 
isolated form and as part of a polyendocrine syndrome [74], while 17-OH and 
especially SCC are the main gonadal autoantigens [75]. Autoantibodies directed 
against tryptophan hydroxylase (TPH) and aromatic L-amino acid decarboxylase 
(AADC) are also highly precise in their detection of APS-I and correlate to 
malabsorption and hepatitis, respectively. They are rarely seen in other conditions 
except in a subgroup of AADC-positive Addison’s patients [70, 76, 77]. 
Autoantibodies against tyrosine hydroxylase (TH) are correlated to alopecia in APS-I 
[72], and autoantibodies against TH is also seen in isolated alopecia and viteligo [78, 
79]. Autoantibodies against glutamic acid decarboxylase 65 (GAD65) are commonly 
found in insulin dependent diabetes mellitus [80], and are also common in APS-I, 
although associated with intestinal dysfunction [57].  
 
Autoantibodies against NALP5 are specific for APS-I, and a serological sign of 
hypoparathyroidism. NALP5 is also expressed in ovaries, and anti-NALP5 is 
suggested as a marker of primary ovarian failure.  This is yet to be confirmed, as all 
investigated NALP5 positive patients had hypogonadisms in combination with 
hypoparathyroidism [55]. Autoantibodies against the calcium-sensing receptor 
(CaSR) are also related to hypoparathyroidism [81]. Although controversial [57], 
CaSR has been confirmed as a receptor-stimulating antigen in a limited number of 
APS-I patients [82, 83].  
 
As these antibodies are quite specific for either APS-I or a specific phenotype (Table 
1), a probable diagnosis can be made from any disease-component together with 
autoantibodies against NALP5, AADC, TPH or TH. 
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Cytokine autoantibodies in APS-I 
The cytokine autoantibodies recently described in APS-I patients have changed the 
view on autoantibodies in endocrine diseases, as they no longer only are directed 
against organ-specific antigens, but also against components of the immune system 
itself. The first cytokine autoantibodies described in patients with APS-I were those 
against type I interferons (IFNs) [84], followed recently by Th17-derived cytokines 
[85, 86].  
 
Interferons type I 
The IFNs were first recognised in 1957 as substances with antiviral activity that are 
secreted from cells in response to a variety of stimuli [87]. Type I interferons are a 
large group of structurally similar cytokines, grouped into IFN-, (with more than 13 
different members), IFN-, IFN-, IFN- and IFN- in humans. They are encoded by 
genes clustered in one locus on the human chromosome 9. IFN-, IFN- and IFN- 
are expressed at very high levels in plasmacytoid DCs and monocytes following viral 
infection, exposure to double-stranded RNA or stimulation through Toll-like 
receptors, and are early key players in the innate immune response [88, 89]. They 
signal through the Jak-Stat and mitogen-activated protein kinase (MAPK) pathways 
through the same receptor composed of the IFN-R1 and IFN-R2c subunits. In 
autoimmunity, the type I IFNs have a dual role, both promoting and restraining 
autoimmunity and inflammation [90-92]. This is best exemplified by the human 
diseases systemic lupus erythematous (SLE) and multiple sclerosis (MS), where the 
type I IFNs promote autoimmunity and inflammation in SLE [93], but have a 
protective and therapeutic role in MS [94]. Autoantibodies against type I IFNs, 
namely against IFN-, were first described in patients suffering from myasthenia 
gravis (MG) and thymoma in 2001 [95]. MG is a neuromuscular junction disease, 
characterised by autoantibodies against acetylcholine receptor (AChR) [96], while 
thymomas are histological heterogeneous tumours consisting of thymic epithelial 
cells [97-100]. Fifteen per cent of the MG patients develop thymoma, and 
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autoantibodies against titin and ryanodine receptor identifies ninety-five per cent of 
these patients. On the other hand, fifty per cent of the thymoma patients develop MG 
[96].  
 
Autoantibodies against IFN type I in APS-I 
In 2006, neutralising autoantibodies against IFN-type I were detected in patients 
suffering from APS-I; surprisingly anti-IFN- was found in all the investigated 
patients [84]. Several studies utilising different methods, control groups, and 
including large number of patients from different countries have confirmed the 
presence of anti-IFN- in close to every patient diagnosed with APS-I [84, 101, 102]. 
These autoantibodies also seem to precede clinical symptoms, and have been detected 
as early as 7 month of age [103]. Utilising autoantibodies against IFN- has therefore 
the potential as a valuable diagnostic marker, and are suggested as a simpler and 
faster diagnostic tool preceding AIRE mutational analysis [101]. A probable APS-I 
diagnose can consequently rely on the presence of anti-IFN- together with any 
disease-components (Fig. 2) [50]. The origin and role of these autoantibodies are still 
unclear, but autoantibodies against IFN- have been shown to down-regulate 
interferon-stimulated gene expression in blood cells from APS-I patients [104]. The 
autoantibodies against IFN- and IFN- are also found in patients suffering from MG 
and thymoma, and their shared thymic dysfunction has been suggested as a possible 
connecting point.  
 
Interleukin 17A, 17F and interleukin 22 
The leukocyte-derived cytokines interleukin (IL) 17-A, IL-17F and IL-22 belong to a 
class of cytokines with a predominant effect on epithelial cells in various tissues. 
They are mainly produced by Th17 cells (Fig.1), which were identified as an 
independent linage of CD4+ T cells in 2005 [105]. But also other immune cells, both 
adaptive and innate may produce these interleukins (Table 2).  
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IL-17A and IL-17F belong to a family of six identified proteins named from A to F, 
where the IL-17A and IL-17F genes, located on chromosome 6, share fifty per cent 
homology [106-109]. IL-22 is a member of the IL-10 family, together with IL-10, IL-
19, IL-20, IL-24 and IL-26, and the IL-22 gene is located on chromosome 12 [110, 
111]. 
 
Table 2. The human IL-17 and IL-22 producing immune cells and their properties.  
Cell 
type 
Secreted 
cytokine 
Other secreted 
factors 
Transcription 
factor 
Surface markers Ref. 
Adaptive 
Th17 IL-17, IL-22 
IL-21, IL-26, TNF-, 
CCL20 
RORt 
CD4+ CCR4+ CCR6+ 
CXCR3- CD161+ 
[112-
114] 
Th22 IL-22 TNF-, FGFs Unknown 
CD4+ CCR4+ CCR6+ 
CCR10+ 
[30, 31] 
Innate 
NKT IL-17, IL-22 IFN- ROR CD3+ CD56+ 
[115-
117] 
LTi IL-17, IL-22 
TNF-, 
Lypmphotoxin 
RORt 
CD3- CD56- NKp44+ 
NKp46+ CD117+ 
CD127+ CD161+ 
[118] 
RORC+ 
NKp46 
IL-17, IL-22  RORt 
NKp46+ NKG2D+ 
CD117+ CD127+ 
[119] 
NK22 IL-22 
IL-26, leukaemia 
inhibitory factor 
RORt 
CD3- CD56+ NKp44+ 
CCR6+ 
[120] 
        Modified from Eyerich et al, Trends in Immunology 2010 [121]. 
TNF-; tumour necrosis factor alpha, CCL; Chemokine (C-C motif) ligand, CD; Cluster of Differentiation, CCR; 
C-C Chemokine receptor, CXCR; CXC Chemokine receptor, FGFs; Fibroblast Growth Factor, NKT; Natural Killer 
T cells, LTi; Lymphoid tissue inducer cell, RORt; RAR-related orphan receptor gamma. IL-17 includes both 
IL17-A and IL17-F. 
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IL-17A, IL-17F and IL-22 have an overall function in the epithelial cells of barrier 
organs, where they defend the host against extracellular pathogens. They activate 
innate immune responses in tissue-cells, recruit immune cells by the induction of 
different chemokines, cytokines, inflammatory and antimicrobial proteins, and also 
have a regenerative effect on tissue after inflammation [121]. 
 
The proinflammatory cytokines IL-17A and IL-17F are secreted as disulphide-linked 
homo- or hetero-dimers [106, 107, 122]. They interact with their shared homo- or 
heterodimeric receptor consisting of IL-17RA and IL-17RC [123], which result in 
transcriptional activity of the nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-B) [124], or activation of the MAPK pathway, where IL17-A acts 
through p38, and both IL17-A and IL17-F can activate the extracellular signal-
regulated kinase (ERK) [125, 126]. Genes expressed in response to IL-17A and IL-
17F encode IL-6, granulocyte-colony stimulating factor, tumor necrosis factor (TNF) 
, chemokines CXCL1, CXCL2 and CCL20, acute-phase proteins, complement 
system factors, and antimicrobial proteins like defencins and mucins (Fig. 3) [127]. 
Both IL-17RA and IL-17RC have a wide range of expression; IL-17RA on epithelial 
cells, fibroblast, macrophages, DCs, vascular endothelial cells and peripheral blood T 
cells [128-131], and IL-17RC on tissue cells of prostate, cartilage, kidney, liver, heart 
and muscle [132, 133]. 
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        Modified from Eyerich et al, Trends in Immunology 2010 [121]. 
Figure 3. Simplified presentation of the IL-17A, IL17F and IL-22 signalling. The left part of the 
figure represents the signalling by IL-17A and IL17F, which bind their shared receptor as disulphide-
linked homo- or heterodimers. This induces transcriptional activity of NFB, or activation of the 
MAPK-pathway and transcriptional activator protein 1 (AP-1), which result in the release of factors 
that activate the innate immune system and recruit immune cells. The response to signalling by the 
homodimeric IL-22 is represented on the right part of the figure, where activation of MAPK and 
transcriptional activity through STAT3 result in release of proinflammatory, antimicrobial and acute 
phase proteins.   
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Secreted IL-22 can create opposite effects, depending on the cytokine milieu. IL-22 
on its own has a regenerative and protective effect on tissue cells, while secreted 
together with TNF-, IFN-, and/or IL-17A and IL-17F, IL-22 increases the 
inflammatory immune response [30, 134]. IL-22 also forms a homodimer [135] 
before interacting with its heterodimeric receptor consisting of IL-10R-chain and 
IL-22R [111]. IL-22R is exclusively expressed on tissue cells at outer body barriers, 
and is absent from cells of the immune system. Thus, IL-22 communicates will 
epithelial cells and not immune cells. This is in contrast to the usual designation of an 
interleukin, as immune cells are not the target for IL-22 [136]. One possible 
exception is one report of IL22R on monocyte-derived human macrophages [137]. 
The interaction of IL-22 to IL-22R enables the subsequent binding of IL-10R and 
phosphorylation of the tyrosine kinases Jak1 and Tyk2, associated with IL-22R and 
IL10, respectively. This activates signal transducer and activator of transcription 
(STAT) 3 [110], and the MAPK pathways of ERK, c-Jun N-terminal kinase (JNK) 
and p38 kinase [138-140]. This again induces expression of proinflammatory genes 
[141], as well as genes encoding antimicrobial peptides, acute phase response 
proteins with predominantly effect on cellular differentiation and mobility of 
keratinocytes (Fig. 3) [140, 142].  
 
IL-17A, IL-17F and IL-22 in human disease 
IL-17A, IL-17F and IL-22 in Chronic Mucocutaneous Candidiasis  
In patients with isolated CMC, decreased levels of IL-17A, IL-17F and IL-22 are 
found after stimulation with C. albicans. Since these patients also have a reduced 
number of IL-17 producing cells, a defect in their T cell compartment is a likely 
explanation [143]. Patients diagnosed with autosomal-dominant hyper-IgE syndrome 
lack production of IL-17 and are therefore susceptible to CMC due to their mutation 
in STAT3 [144], which  affects the expression of the Th17-spesific transcription 
factor RORt [145]. In addition, a recessive inherited mutation in IL-17RA, and 
dominant inherited mutation of IL-17F both result in development of CMC [146], 
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underlining the importance of IL-17 in defence against C. albicans. Among the 
antimicrobial proteins produced in response to IL-22, the S100 protein family and 
human  defensin 2 are known to protect against C .albicans [147, 148].  
 
In autoimmune disorders 
The effect of the Th17-derived cytokines in autoimmune diseases is best illustrated 
by IL-17A in Rheumatoid Arthritis (RA) where the level of IL-17A is up-regulated in 
the rheumatoid synovium. This promote inflammation and bone destruction in vitro 
by the pro-inflammatory cytokines TNF-, IL-, and IL-6. As IL-6 maintains the 
Th17 T cell population, a chronic inflammatory state is established [127]. The role 
for IL-22 in RA is more obscure, but it could have a pathogenic role by promoting 
inflammatory responses in synovial tissue [139]. In SLE patients, a decrease in 
circulating IL-22 levels is found to be correlated with disease activity [149, 150], 
while increased levels of IL-22 are found in inflamed region of the colonic mucosa in 
ulcerative colitis and Crohn’s disease [138, 151]. In the autoimmune skin-specific 
psoriasis, high expression of IL-22 is found in psoriatic skin, and there is a 
correlation between the levels of IL-22 in blood and the severity of the disease [136, 
140].  
 
Autoantibodies against IL-17A, IL-17F and IL-22 in APS-I 
The high occurrence of CMC in patients with APS-I was long regarded as an immune 
defect and not as a part of the autoimmune reaction. The current discovery of 
autoantibodies against IL-17A, IL-17F and IL-22 in sera from APS-I patients 
indicates an indirect autoimmune cause of CMC, where these autoantibodies inhibit 
elements in the defence against C. albicans [85, 86]. Interestingly, patients suffering 
from thymoma and CMC in combination are also positive for these autoantibodies 
[85]. The Th17-response towards C. albicans has been studied using peripheral blood 
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mononuclear cells (PBMC) from APS-I patients, where the production of IL-17F and 
IL-22 were down-regulated, while the results for IL-17A were unequivocal [85, 152].  
 
The Autoimmune regulator gene 
The autoimmune regulator gene, AIRE, was identified as the underlying cause of 
APS-I in 1997. It occupies 13 kilo bases on chromosome 21, harbouring 14 exons 
which encode a 545 amino acid protein [153-155]. Over 60 different mutations have 
been identified, among them, one dominant negative mutation [156]. Mutations are 
found in ninety-five per cent of the clinical APS-I cases [157], and are routinely 
searched for when APS-I is suspected. The high number of mutations found 
throughout the coding region of AIRE does not explain the large phenotypic variation 
seen in the patients, which might rely on other genetic or environmental factors [61, 
158]. The only exceptions might be the association of chronic mucocutaneous 
candidiasis with the most common Finnish mutation, p. R257X [85], and the low 
frequencies of AAD and CMC in patients with the Iranian Jewish p.Y85C mutation 
[159].  
 
The large numbers of mutations spread throughout AIRE have had an important role 
in revealing the properties of the AIRE protein, a field that has grown tremendously 
over the past couple of years.  
 
Localisation and expression of AIRE 
Within the cells, AIRE is found in the nucleus, in nuclear bodies, visualised as 
discrete dot-like structures [160-162]. AIRE is mainly expressed in the thymus in 
both human and mice, by a subpopulation of medullary thymic epithelial cells 
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(mTECs), characterised by high expression levels of MHC class II and the co-
stimulatory markers CD80, CD86 and CD40 [161, 163, 164].  
 
In the human peripheral immune system, AIRE is expressed in lymph nodes, spleen, 
tonsils, gut-associated lymphoid tissue and fetal liver [154, 161, 165], and by cells of 
the immune system, notably in B-cells, macrophages and DCs [165-167]. In mice, the 
results differ slightly regarding the different genetic backgrounds [168], and 
expression is mainly seen in lymph nodes and spleen, [164, 169-176], but also 
identified in liver, brain [176] and testis [171]. However, expression is only detected 
at mRNA-levels in immune cells, where it is found in monocyte-derived DCs, 
plasmacytoid DCs and myeloid DCs [175]. 
 
AIRE; protein domains and function 
The observation that AIRE localises to the cell nucleus, together with the 
characterisation of its functional domains, were the first clues pointing to a role as a 
transcriptional activator. The functional domains includes a nuclear localisation 
signal, two plant homeodomain zinc finger (PHD) motifs, four LxxLL nuclear 
receptor binding motifs, a proline-rich region, a caspase-recruitment domain (CARD) 
and a SAND domain (named after the proteins Sp100, AIRE-1, NucP41/75 and 
DEAF-1) (Fig. 4) [153, 154, 177-179]. When fused to a heterologous DNA binding 
domain, AIRE activates transcription of a reporter gene, and the CARD domain (long 
referred to as a homogeneously staining domain, HSR,), mediating AIRE-AIRE 
homodimerization, is needed for this activation [180, 181]. AIRE binds DNA as a 
dimer or tetramer [182], and both PHD-domains and the SAND-domain have DNA-
binding abilities in vitro [179]. 
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        Modified from Peterson et al, Nature Reviews Immunology 2008 [183] 
Figure 4. Schematic overview of AIRE. The figure shows the functional domains and their 
localisation within the AIRE protein, with the corresponding number of amino acids and the regions 
necessary for transcriptional activation indicated above. The N-terminal caspase-recruitment domain 
(CARD) is necessary for nuclear dot formation and has been implicated in homo- or hetero-
oligomerisation of the protein. The nuclear localisation signal (NLS) is targeting the protein to the cell 
nucleus, while the SAND domain is a putative DNA binding domain. AIRE has two plant 
homeodomains (PHD) zinc fingers, the first (PHD1) has been shown to interact with unmetylated 
histone H3 lysine4 and with the DNA-dependent protein kinase complex, and both interactions are 
required for proper transactivation. PHD1 has also been shown to have E3 ubiquitin ligase activity, 
which is an enzymatic process where an ubiquitin molecule is added to a target protein, as a marker 
for degradation. The two PHD domains are also found to bind to specific DNA motifs. Four LXXLL 
motifs (L) are found throughout AIRE which is a small motif found in many transcriptional co-
activators. Its function in AIRE is still to be discovered together with the function of the proline-rich 
region (PRR). 
 
Studies from mice have been particularly powerful in elucidating the function, 
localisation, and structural organisation of its human counterpart, and have proved 
Aire to be a key transcriptional regulator of the immune system [169, 184-186]. Aire 
binds in vivo to specific DNA-sequence motifs and regulate the thymic expression of 
a broad spectrum of genes, including autoantigens, cytokines, transcription factors 
and posttranslational modifiers [187].  
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AIRE in the thymus and in tolerance 
Thymus and central tolerance 
The thymus is the main organ for lymphoid cell differentiation and selection, both 
which are processes that rely on a dynamic relocation of developing lymphocytes 
within the thymic microenvironment. Thymocyte survival and commitment to linage 
is dependent upon discrimination of self- versus non-self, and may induce cell death 
through positive or negative selection. When lymphoid progenitor cells enter the 
thymus, CD4+CD8+ double positive (DP) thymocytes are generated in the outer 
cortex, with their T cell receptor (TCR) present on the surface. Here, they undergo 
positive selection, where the DP thymocytes displaying TCRs with no affinity to 
MHC undergo apoptosis, while those able to bind MHC class I or II survives and 
commits to the CD4+ or CD8+ lineages. These SP thymocytes then migrate to the 
thymic medulla where they interact with mTECs which expose them to a wide array 
of peripheral tissue antigens (PTAs). Thymocytes expressing TCRs with high affinity 
for self-antigens are deleted, in the process of negative selection. The presentation of 
PTAs by the mTECs and the elimination of self-reactive T cells are crucial to induce 
immunological tolerance and to prevent autoimmune disease. This stringent selection 
process leaves only one to three per cent of the lymphoid cells to escape into the 
periphery [188, 189].  
 
Aire in central tolerance 
The great repertoire of PTAs exclusively expressed in the mTECs are continuously 
transcribed during the period of T cell output [163], and are conserved between 
humans and mice [190]. They are diverse in their gene ontology, tissue specificity 
and chromosomal location, and tissue restricted genes are overrepresented [191, 192]. 
These observations pointed early to the involvement of epigenetic mechanisms in 
controlling the transcription of PTAs [193]. Some of the PTAs, e.g. thyroid 
peroxidase, thyroglobulin, the P450 cytochrome subfamilies and IA-2, are found to 
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be autoantigens in patients with APS-I, and linked AIRE to the regulation of PTA 
transcription [190]. In Aire knockout models a reduction or total loss of transcription 
of Aire-regulated PTAs were seen [194], leading to the escape of autoreactive T cells 
into the periphery [191].  
 
Aire possesses multiple roles in the activation and transcription of genes [195]. At the 
epigenetic level, Aire’s PHD1-domain interacts with unmethylated lysine 4 of histone 
3 (H3K4me0), a marker of transcriptionally inactive chromatin [193, 195-197]. 
Transcriptional activity is then induced when Aire associates with factors promoting 
elongation of the transcript, as part of the early-acting elements of the non-
homologous end-joining DNA repair machinery. This complex resolves DNA-
supercoiling by creating single- and double-stranded breaks in the DNA, promoting 
unwinding and subsequent religation. Aire is also involved in the processing of pre-
mRNA to mature mRNA, which is thought to take place in the nuclear speckles. By 
these mechanisms, Aire enhances transcription of weakly expressed peripheral tissue 
antigens in MECs, peptides from which can be presented via MHC class I or II to 
immature thymocytes. High avidity interactions between these peptide/MHC 
complexes and the T cell receptors of self-reactive T cells will eventually result in 
their apoptosis [195]. The molecular basis of how AIRE regulates transcription of 
PTAs in mTECs has yet to be confirmed in non-transgenic settings and in humans.  
 
AIRE and DCs 
The APS-I patients display normal levels of plasmacytoid and myeloid DCs in blood 
[104, 198]. However, after stimulation with C. Albicans, the monocyte-derived DCs 
from APS-I patients expressed less cytokines, in particular IL-10, TNF- and 
CXCL10, compared to controls. In addition, the expression of genes involved in 
immune regulatory pathways of cell-cell signalling and cytokine production was 
reduced [167]. In transgenic mice, Aire mediate thymic deletion of CD4+ T cells 
independent of PTA expression, by indirect presentation of mTEC-derived PTAs by 
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bone marrow derived cells. Therefore, some antigens rely on DCs for presentation to 
maturing thymocytes, where Aire is necessary for the transfer of antigen from the 
mTECs to the DCs [199-201].  
 
Aire in peripheral tolerance 
Although tightly controlled, some autoreactive T cells escape thymic negative 
selection and are released into the periphery. Peripheral tolerance is aimed to delete 
or inhibit activation of these T cells when they encounter their tissue-restricted self-
antigen [202-205].  
 
A role for Aire in peripheral tolerance is emerging, but the details are still unclear. A 
new subset of Aire-expressing extrathymic cells (eTACs) were identified in the T 
cell- B cell boundary regions in lymph nodes and spleen in a transgenic model system 
in 2008 [174]. Although they share certain characteristics with mTECs, they are a 
distinct cell type, as they do not express the co-stimulatory molecules CD80 and 
CD86, and the genes regulated by mTECs and eTACs  show little overlap [174]. 
Naïve T cells are frequently trafficking the secondary lymphoid organs, and PTA-
expression is therefore likely to occur there [206]. The eTACs probably play an 
important role in the deletion of peripheral autoreactive T cells and the maintenance 
of tolerance, although Aire-independent expression of tissue-restricted mRNA has 
been identified in stromal cell subsets in the lymph nodes [207, 208]. 
 
Treg cells in peripheral tolerance 
The Treg cells are a specialised CD4+ T cell linage, crucial for maintaining peripheral 
tolerance, as they counteract Th1 and Th17 responses in order to avoid tissue damage 
(Fig.1). Their suppressive activities rely on activation of their TCR by APCs. Once 
activated, a Treg cell can suppress a broad range of immune reactions, independent 
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on the initial, activating antigen [209]. The underlying suppressive mechanisms are 
still poorly understood, but probably involve direct cell-contact and secretion of 
inhibitory cytokines [210].  
 
Their critical role in preventing autoimmunity is best demonstrated by the fatal, 
multi-organ autoimmune disease IPEX, characterised by the occurrence of diarrhoea, 
type 1 diabetes, thyroiditis, and eczema. IPEX is caused by mutations in the Treg 
transcription factor gene, FOXP3, resulting in defective Treg cells [211]. Deficient 
Treg cells are also associated with more common autoimmune diseases, like type 1 
diabetes, MS and RA [209, 212]. Treg cells from APS-I patients have decreased 
levels of FOXP3-expression, and a limited clonal expansion in the TCR-repertoire is 
seen, together with failure to activate the Treg cells [213, 214].  
 
Th17, Treg cells and autoimmunity 
There is shown to be a balance between the Th17 and the Treg cells (Fig. 1), and the 
plasticity between these two lines of Th cells may tip the scale in favour of the 
effector Th17 subset and autoimmunity. The anti-inflammatory cytokine 
transforming growth factor (TGF)  is needed for the generation of both Th17 and 
Treg cells from naïve CD4+ cells, and expressed together with IL-6, TGB- will 
promote the Th17 subset [215]. IL-6 is expressed during injuries, infections and 
inflammation, and inhibits expression of Foxp3 in mice [215]. Both retinoic acid and 
the Treg growth factor, IL-2, promote Treg differentiation, while preventing the 
expression of Th17 cells [216, 217]. At the molecular level, the respective 
transcription factors of Th17 and Treg bind each other, thereby inhibiting each 
other’s function [218, 219]. The balance of Th17 and Treg cells and the proper 
expression of FOXP3 are crucial to avoid promotion of autoimmunity [220, 221]. 
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Information gained from the study of APS-I 
As a monogenetic disease, the study of APS-I and AIRE have proved to be 
particularly informative regarding the establishment of tolerance and the transcription 
of PTAs. Defects in both central and peripheral tolerance pathways that contribute to 
autoimmunity has been recognised [157], and the identification of AIRE has 
expanded our knowledge about immune tolerance and emphasised the importance of 
a functional thymic environment in the prevention of autoimmunity [222]. This is of 
relevance for more common endocrine autoimmune disorders, exemplified by the 
thymic PTA-expression in type 1 diabetes, where the transcription levels of insulin in 
thymus correlates to lower risk of disease [223, 224].  
 
Only a few autoimmune diseases follow a monogenic inheritance pattern and the 
study of these diseases has revealed valuable information about their molecular 
pathogenesis and about affected and normal physiology. A further understanding of 
the genetics and the molecular mechanisms behind autoimmunity will hopefully lead 
to new therapeutic strategies [225].  
 
 39
Aims of study 
A translational approach to APS-I and AIRE is important to expand our knowledge 
not only on this rare autoimmune disease, but also to understand general mechanisms 
of autoimmune diseases.  
 
In this work we addressed the lack of rapid and robust assays for APS-I. Moreover, 
we sought to find new mutations in AIRE and to see if variations in AIRE were 
involved in more common autoimmune diseases. Finally, we explored cellular 
immunity by studying immune cell subsets in order to understand the immune defect 
involved in multi-organ autoimmunity. 
  
The specific aims were:  
I. To develop specific diagnostic assays for the detection of APS-I patients. 
Radioimmunoassay is a well-established method for the analysis of 
autoantibodies, and was chosen as the technique for establishing novel 
cytokine autoantibody assays detecting patients with APS-I. 
II. To investigate if genetic modifications of AIRE, both variations in copy 
number and single nucleotide polymorphisms, were associated with AAD. 
III. To learn more about cellular immunity in APS-I by studying immune cells in 
Norwegian APS-I patients, their relatives and healthy controls.  
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Methodological considerations 
Patient samples (Paper I, II, III, and IV) 
The Norwegian patient and control material used in these studies were gathered from 
ROAS, comprising samples from 50 APS-I patients (11 diseased), and ~500 patients 
with AAD and APS-II. Regarding APS-I, their age, gender and time of diagnosis 
together with their clinical phenotype and mutational status are described (for details, 
see Appendix I). Anonymous healthy controls were recruited from the blood bank at 
Haukeland University Hospital; one group completely anonymous, and one group 
with a few known variables, like age and gender. All patients and controls signed an 
informed consent according to the declaration of Helsinki when included in ROAS.  
 
AAD-patients with APS-I-like features (Paper I) were selected on one of the 
following criteria  
• AAD onset before the age of 20 years 
• autoantibodies against TPH, TH, AADC or SCC  
• presence of ectodermal manifestations associated with APS-I 
 
In Paper II, blood sera from a total of 48 APS-I patients of Norwegian (n=32) and 
control sera from their first-degree relatives (n=10), patients with AAD (n=354), type 
I diabetes (n=38), and healthy controls (n=150) were included from ROAS. In 
addition, Finnish (n=6), Swedish (n=7) and North-American (n=3) APS-I sera were 
included, together with control sera from Swedish patients with Down syndrome 
(n=45), all recruited through our international collaborators.  
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Analyses of the AIRE gene (Paper I) 
SNP analysis of the AIRE gene 
Variations of single nucleotides polymorphisms (SNPs) within the DNA-sequence 
have been shown to cause different human diseases. When used in association 
studies, a polymorphism must occur more or less frequently than what is expected by 
chance. By utilising LD, association between alleles at different loci are measured, 
expecting that the frequency of finding two loci together is different from the 
frequencies of the respective loci. As the common variations in the human genome 
can be arranged as haplotypes within blocks of strong LD, they reduce the need of 
multiple tests over single SNPs. In this candidate-gene association study (Paper I), 
the occurrences of SNPs within and in close-proximity to AIRE was investigated in 
311 patients with AAD, either isolated or as part of APS-II, and in 521 healthy 
controls to reveal any association between polymorphisms and disease. Nine SNPs 
covering AIRE and its flanking regions were chosen based on Hap Map data  and 
earlier work by Turunen et al. [226]. All primers and probes used in the Taqman 
allelic discrimination assay were commercially available from Applied Biosystems 
(Carlsbad), and DNA for all genetic analysis was extracted from frozen blood 
samples using standard molecular procedures. 
 
Copy number variation (CNV assay) of AIRE 
Alteration of DNA in a genome might result in an abnormal number of copies of one 
or more sections of DNA within the cells of the organism. These relatively large 
regions of DNA, ranging from one kilo base to several mega bases, are either deleted 
(low copy number) or duplicated (high copy number). Duplex Taqman real-time PCR 
assay can detect variations in copy number of AIRE between patients with AAD or 
APS-II and controls. For each patient sample run in duplicate, fluorescent signals 
were detected using probes for the target gene AIRE and for the reference gene Rb-1 
(Retinoblastoma-1) [227], known to have a copy number of two in the genome. The 
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relative relationship between AIRE (unknown number of copies) and Rb-1 (two 
copies) gives the copy number of AIRE using a standard curve for each gene. Primers 
and probes were designed using Beacon Designer v. 2.1, (Premier Biosoft 
International), and all reagents were available from Applied Biosystems.  
 
Genetic analysis and statistics 
Data from SNP analysis were analysed by ABI 7900HT Genetic Analyser and SDS 
2.1/2.2 software (Applied Biosystems). Data from haplotype mapping (Hap Map) 
were used to tag all known variations with a 5% minor allele frequency. A pairwise 
tagging method and cut-off were used, and r20.8 by the Haploview software [228]. 
Single point analysis and estimation of haplotype were performed using Haploview 
and Unphased software.   
 
Immunological methods (Paper I, Paper II and Paper IV) 
Radioimmunoassay of autoantigens 
Radioimmunoassay (RIA), also termed radio-ligand binding assay (RLBA), is a well-
known and well-used method to determine the presence of autoantibodies, and may 
be utilised on a variety of fluids from patients, including blood, sera, and saliva. RIA 
is a fluid-phase immune precipitation method, based on in vitro transcribed and 
translated antigens, labelled with 35S methionine. When added to patient sera, the 
antigen will be bound by autoantibodies if present. This complex is then captured by 
immune precipitation with protein A-sepharose and will yield a radioactive signal 
quantified in a scintillation counter [70]. In the development of the anti-IFN- assay 
(Paper II), 0.1% dithiothreitol (DTT) was included when incubating the sera with 
antigens overnight, to reduce the two disulphide bonds present in IFN- and to 
prevent the formation of intra- and inter- molecular disulphide bonds between the 
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cysteine residues in the proteins. This yielded better discrimination between positive 
and negative control-sera, hence expanding the range of detection without 
introducing false positives (FP). 
 
The samples from patients and controls were tested as duplicates (Paper IV) or 
triplicates (Paper I, II and III). IgG were purified as described by Ey et al. [229] 
(Paper II), and blood sera were used in the detection of autoantibodies (Paper I, II, 
III and IV). 
 
Design of fusion proteins for the detection of anti- IL-17F and anti-
IL-22 (Paper IV). 
To overcome the low incorporation of 35S methionine obtained from the in vitro 
expression of IL-17F and IL-22, a method expressing dimers was chosen, as these 
interleukins also are shown to be biological active as dimers. In an attempt to detect 
both interleukins with one method, based on their shared correlation to CMC, an 
additional chimeric DNA-construct of IL-17F and IL-22 was made (Paper IV). In 
general, the 5’ end of the first part in the fusion-protein cDNA was inserted into the 
expression vector pcDNA3, using primers where the stop-codon was replaced by 
base-pairs coding for methionine. The procedure was then repeated with the second 
cDNA with the original stop-codon, fulfilling the dimer-and chimeric constructs. The 
constructs were verified by sequencing to ensure no mismatch in the open reading 
frame before utilising them for protein expression.  
 
Analysis of data, determination of normal range and validation of 
the RIAs (Paper II and IV) 
The results from the different RIAs were expressed as index-values {(counts per 
minute (cpm) sample – cpm negative control/cpm positive control – cpm negative 
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control) × 1000}, where pooled human serum from healthy donors was used as 
negative control, and an APS-I serum with medium/ high antibody levels against the 
antigen tested, as positive control. The normal limit for each assay was calculated as 
the mean of at least fifty healthy controls + three standard deviations (SD). 
Coefficient of variation (CV) {(CV (%) = (SD/mean) × 100} and inter- and intra-
variability were calculated based on two APS-I sera tested at least three times.  
 
To confirm the specificity in which each assay detected its designated cytokine, one 
APS-I serum was pre-incubated with increasing amounts of non-radioactive antigen; 
IFN- (BMS308, Bender MedSystems), IL-17F (1335-IL-025/CF, R&D Systems) or 
IL-22 (782-IL-101/CF, R&D Systems). Ovalbumin (A 5503-1G, Sigma-Aldrich) was 
used as control. For each assay, the sensitivity {true positives (TP) / (TP + false 
negatives (FN))} and specificity {true negatives (TN)/(TN + FP)} in which the assays 
detected APS-I (Paper II) and CMC (Paper IV) were calculated. 
 
Flow cytometry (Paper III) 
To analyse the different subsets of immune cells from APS-I patients, blood 
mononuclear cell immunephenotyping of 19 patients with APS-I, 18 first degree 
relatives and corresponding sex- and age-matched controls were analysed by the 
multi-parametric method flow cytometry (Paper III). PBMC from patients and 
controls were isolated from EDTA-blood using Lymphoprep (Axis-Shield PoC AS), 
and a total of 2 × 105 cells in a volume of 100 	l were incubated with labelled 
monoclonal antibodies (Becton Dickinson (BD) Biosciences) against human cell 
markers. The isolated PBMCs were washed, before they were fixated in 1% 
paraformaldehyde. Four markers were analysed simultaneously by FACS Calibur 
(BD Sciences) and FLOWJO version 7.2.5 (Tree Star).  
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To estimate the number of type-1 myeloid dendritic cells, type-2 myeloid dendritic 
cells and plasmacytoid dendritic cells, the human blood dendritic cell enumeration kit 
from Miltenyi Biotech (Bergisch Gladbach) was employed. 
 
Statistic methods Paper II, Paper III, Paper IV 
Differences between immune cell subsets from APS-I patients and the controls (age 
and sex-matched), and between the family members and controls (age and sex-
matched) were calculated by Mann-Whitney test in SPSS v.15 (SPSS Norway AS) 
and/or GraphPad v.5 (GraphPad software Inc). P-values below 0.05 were considered 
statistically significant (Paper III). Correlations between RIA and ELISA (Paper IV) 
were calculated by Spearman r-test, confident interval and P-value using Graphpad 
v.5.02. Fisher’s exact test was used to calculate statistical association of IFN- 
antibodies in APS-I patients compared to the control groups by SPSS (Paper II).    
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Summary of results 
Paper I 
AAD is often associated with other autoimmune symptoms as part of an autoimmune 
polyendorine syndrome, and several genes have been associated with AAD, in 
particular MHC [230-234], cytotoxic T lymphocyte antigen 4 (CTLA4) [235-237] and 
protein tyrosine phosphatase non-receptor 22 (PTPN22) [238]. This paper 
investigated whether variations in AIRE could be involved in increased susceptibility 
to AAD in a three-pronged approach: (i) association analysis using nine SNPs within 
and in close proximity of the AIRE gene, (ii) sequencing the AIRE gene in candidate 
AAD patients in order to look for rare polymorphisms, (iii) investigate whether CNV 
of AIRE could be involved. By analysing nine SNPs covering AIRE in 311 patients 
with AAD and in 521 healthy controls, the pattern of LD was found to be similar to 
the Hap Map data. Thus, the nine SNPs analysed identified most of the common 
variation seen, and none of the polymorphisms were associated with AAD. Twenty-
five AAD-patients with APS-I-like features were selected for sequencing of the 14 
exons of AIRE, identifying three novel polymorphisms, two which were considered 
as possible pathogenic variations; (i) c.1411C 
 T, p.Arg471Cys and (ii) c.1507G 
 
A, p.Asp503Asn. Together with a previously described polymorphism, c.901G>A, 
p.Val301Met [239], these were genotyped in 311 AAD patients and in at least 107 
healthy controls in order to investigate their frequencies. 
 
CNV analysis of exon 2 in 161 investigated AAD patients revealed no variation in 
copy number when compared to 39 healthy controls. However, 14 APS-I patients 
were included as a control group, and large deletions in AIRE were detected in two 
patients, together with a disease-causing mutation on the other allele. The first patient 
had a large deletion on one allele, reaching from at least exon 1 to intron 8, which 
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was also found in the healthy mother and two healthy siblings. The second patient 
had a deletion stretching from exon 2 to exon 8.  
 
Taken together, genetic variations in AIRE were not associated with AAD, and the 
new identified SNPs were unlikely to cause an APS-I like phenotype in a 
heterozygote state as they were also seen in healthy controls, however, no healthy 
individual carried  the c.901G>A variant. The finding of large deletions in APS-I 
patients underpin the importance of DNA analysis of parents when APS-I patients are 
found to be homozygote for an AIRE mutation, in order to avoid faulty diagnosis. 
 
Paper II 
Since anti-IFN- appeared as a universal diagnostic marker of APS-I, we aimed to 
develop a reliable, fast and high-throughput immunologic assay to determine the 
prevalence of this autoantigen in a considerably large cohort of APS-I patients of 
different geographic origins. The established RIA detected anti-IFN- positive 
patients with high specificity, demonstrated in competition experiments with non-
radiolabelled antigen. The assay discriminated well between APS-I patients and 
controls, and their anti-IFN- showed little variance over time. One patient with 
AAD had high levels of anti-IFN-; a deceased male patient diagnosed with AAD 
and prolactinoma. No genetic abnormalities in AIRE were found, neither were any 
MG and thymoma-associated antibodies, i.e autoantibodies against acetylcholine 
receptor and titin. A new APS-I patient was detected using this assay, in who 
subsequent mutational analysis of AIRE revealed a homozygote 13 base pair (bp) 
deletion in exon 8, the most common Norwegian mutation, and no abnormalities in 
CNV. This study established a robust immunoassay and confirmed the high 
prevalence of autoantibodies against IFN- in an expanded cohort of APS-I patients 
from different countries, underpinning its diagnostic value.  
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Paper III 
Previous reports regarding characterisation of immune cell subsets in APS-I patients 
have included few patients, and we aimed to characterise immune cell subset in a 
larger cohort of Norwegian APS-I patients and in their close relatives. This was 
performed by extensive blood mononuclear cell immunotyping using flow cytometry. 
Among cell populations with immune regulatory functions, the patients showed 
significantly lower proportions of Treg cells (CD4+CD25+FOXP3+; P = 0.029, and 
CD3+CD4+CD25+CD127-; P = 0.028). Interestingly, in the effector/memory T cell 
subset the Th (CD4+) and Tc (CD8+) T cells were similar in patients and controls, 
except for one family, who’s members had significantly lower frequencies of memory 
Th cells (CD4+CD45RA-CD45RO+) compared to healthy controls (P = 0.023). Th 
cell subsets with homing properties according to differentially expressed chemokine 
receptors CCR6 and CXCR3 were also investigated as CCR6+ cells are attracted to 
epithelial surfaces and CXCR3+ cells to inflammatory tissue. No alteration was seen 
in CD4+CD45RA-CCR4+CCR6+ lymphocytes (containing IL-17A-secreting Th17 
cells), but the percentage of Th cells expressing both CCR6 and CXCR3 (includes 
among others IFN- and IL-17A coproducing cells) were significantly decreased in 
patients (P = 0.035). In general, we found no alterations in the frequencies of DCs in 
this study, while the monocyte subpopulation CD14+CD16+ cells was decreased in 
APS-I patients (P = 0.028).  The Norwegian APS-I patients exhibit a reduced number 
of Treg cells, CCR6+CXCR3+ co-expressing Th subpopulation and CD14+CD16+ 
monocytes, while the previous reported variations seen in invariant natural killer T 
(iNKT) cells and monocytes could not be confirmed in this study. 
 
Paper IV 
Autoantibodies against IL-17F and IL-22 are shown to be associated with CMC; 
however, various assays have differed in their sensitivity detecting these 
autoantibodies. Therefore, we aimed to make a reliable RIA detecting these 
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interleukins both individually and together using a chimeric protein. Furthermore, to 
overcome the generally low incorporation of radioactivity in these short proteins, 
dimeric proteins were designed and tested. The dimers and the chimeric constructs 
regularly incorporated more radioactive methionine than the single interleukins; all 
showed reliable detection of autoantibodies, with satisfying discrimination between 
positive and negative samples. The specificity in their antibody-detection was 
ensured by competition with unlabelled protein. Finally, the results from the RIAs 
were compared to results obtained by ELISA, which revealed satisfying equivalence. 
Unfortunately, the dual detection of IL-17F and IL-22 in one assay, using the dimeric 
protein, could only be verified for IL-22, as all patients with anti-IL-17F also were 
positive of autoantibodies against IL-22. The previously reported correlation between 
IL-22 and the presence of CMC could not be confirmed by this study; instead a trend 
towards association between CMC and IL-17F was seen.  
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General discussion 
Studying a monogenetic disease 
The main challenge to overcome when studying a rare disease is the availability of 
patients and samples, which result in studies with hampered statistical power. The 
extensive use of biological samples require good-will, patience and cooperation from 
our limited APS-I cohort. In Norway, their spread geographical distribution makes 
the sampling of fresh blood for subsequent cell-based analysis challenging, time-
consuming and expensive. It also makes it demanding to obtain accurate patient 
records characterising phenotype and disease status from the different physicians 
treating them.   
 
Extensive international collaboration may resolve some of these problems, as we are 
able to increase the number of patients included in the studies. However, one should 
consider that the genetic background of different populations might influence the 
results. Hence, controls from the same genetic background should be included in 
genetic studies, as exemplified by the great variance seen within European 
populations regarding allele frequencies of the PTPN22 risk-allele [240].  
 
In spite of these challenges, studies of APS-I and the corresponding mouse models 
have led to many important discoveries regarding the establishment and maintenance 
of immunological tolerance. Studies of various Aire knock-out mice have provided 
excellent molecular explanations of how Aire regulate expression of the PTAs in 
thymus, and how Aire is a crucial factor establishing and maintaining central and 
peripheral tolerance [176, 191, 195, 241]. Aire-deficient mice develop multi-organ 
autoimmunity, but the major APS-I manifestations seen in man are not found in the 
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mouse models [176, 191, 241, 242]. Hence, there is a need to study APS-I in both 
men and mice to understand the pathogenesis of the human disease.  
Genetics in autoimmune diseases; APS-I and AAD 
Genetic variations of AIRE have previously been associated with systemic sclerosis 
when combined with thyroiditis [243], and with alopecia [244]. With the function of 
AIRE in regulating expression of PTAs in mind, we investigated whether variations 
in AIRE were associated with AAD, one of the three main components in APSI-I 
(Paper I). Except a c.901G>A polymorphism resulting in a change from a valine to a 
methionine at amino acid 301 (Val301Met) previously reported in one AAD patient, 
we did not find such association. Similar findings were reported in a study of 
association with AIRE and type 1 diabetes [226]. The c.901G>A mutation lies within 
the DNA-binding PHD1-domain of AIRE, and several of the mutations in this area 
are reported as single mutations, i.e. only one mutation has been found in each patient 
[46, 103, 245]. This indicates that a number of unrecognised dominant negative 
mutations could be present among APS-I patients, in a similar manner as the 
dominant pattern of inheritance previously described in the SAND domain of AIRE 
[156].  
 
In addition, we found novel deletions of AIRE, stretching from exon 2 to exon 8 in 
two of the APS-I patients previously thought of as homozygote for the associated 
mutation on the other allele (Paper I). For one of the patients, information for exon 1 
and intron 8 could not be obtained, as the microsatellites were homozygous in these 
areas. These findings emphasise the importance of CNV-analysis when sequence 
analysis fails to detect abnormalities in patients with a clinical APS-I picture. 
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Analysis of autoantibodies 
The presence of autoantibodies is a distinctive and characteristic feature of 
autoimmune diseases. Circulating organ-specific or cytokine autoantibodies is an 
early phenomenon in autoimmune diseases, and can be detected years before clinical 
disease is evident, which makes these autoantibodies excellent markers of disease. 
Autoantibody-analysis of IFN-, 21-OH, SCC, AADC and NALP-5 constitute the 
panel of autoantigens which new patients recruited to ROAS are screened for. 
 
Organ-specific autoantibodies 
Whether the organ-specific autoantibodies are merely markers or serve as mediators 
of disease is still unclear [246, 247], but there are data pointing at a role as enhancers 
of the T cell response against 21-OH [248, 249]. Some autoantigens are shown to 
inhibit the activity of the target enzyme in vitro, like antibodies against AADC [250], 
21OH [251] and GAD65 [252],  
 
Prospective studies show that autoantibodies against 21-OH positively predict 
development of AAD within few years in young APS-I patients [46, 253, 254]. A 
more functional role has been implicated for autoantibodies against the extracellular 
CaSR; A subgroup of APS-I patients were shown to have CaSR-stimulating 
antibodies, leading to lower calcium and hypoparathyroidism, thus reflecting a 
different way of autoantibody action [255].  
 
The pathogenic role of the organ-specific autoantibodies and their underlying 
immunological mechanisms remain to be determined, but their use for diagnostic 
purpose is invaluable.  
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Cytokine autoantibodies 
The origin and function of the cytokine autoantibodies are largely unclear, but the 
autoantibodies against IFN- have shown to be an excellent marker detecting APS-I. 
 
We confirmed IFN- as an antigen in all patients in a relatively large cohort of APS-I 
patients by utilising a novel method ready for high-throughput screening (Paper II). 
This assay is now a routine analysis provided by our research laboratory as part of 
clinical practice, offered through the Hormone Laboratory at Haukeland University 
Hospital. From 2007 until today, we have identified new patients using anti-IFN-, 
where the subsequent genetic analysis of AIRE has confirmed APS-I (manuscript in 
preparation). Among these, we found one family consisting of four affected 
individuals with an unusual dominant inheritance pattern (Erichsen, poster, Endocrine 
Society, 2011) The reliability of the assay and of anti-IFN- as a sensitive and 
predictive marker for APS-I was further confirmed in a multicentre-study including 
174 European patients [101]. Antibodies against IFN- is shown to be a universal 
marker of APS-I, regardless of phenotype and AIRE mutations, and the presence of 
anti-IFN- in sera is now suggested as a diagnostic tool preceding mutational 
analysis of AIRE [101]. 
 
The presence of CMC as one of the three major components of APS-I has puzzled 
scientists for years. The identification of the Th17 derived cytokines as autoantigens 
in APS-I identified CMC as part of the autoimmune reaction and not as an immune 
defect. Due to technical difficulties in expressing high amount of radiolabelled IL-
17F and IL-22 in use for RIA, different dimers were designed in this project, and 
thought to mimic their biological function, as these interleukins bind their receptor as 
dimers. Including the monomers, dimers and the fusion protein of IL-17F and IL-22, 
a total of five RIAs were established, all shown to be highly sensitive and specific in 
their detection of these interleukins (Paper IV).  
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Choice of immunological methods 
The cytokine autoantibodies have mainly been discovered by utilising antiviral 
interferon neutralising assay (AVINA). A major drawback with this method is the use 
of cytolytic virus, demanding a restrictive laboratory procedure. It is also proven 
difficult to standardise the method between laboratories. The biological activity 
exerted by the individuals’ autoantibodies is detected with this assay [84], but as the 
level of viral infections seem to be normal in APS-I, these assays are suggested to 
exaggerate the neutralisation potential of the autoantibodies [256]. The final result, 
measured by AVINA or RIA, appeared to be highly consistent when a third of the 
patients included in the large European study were analysed by both methods [101], 
and this was also the result in Paper II. 
 
Enzyme-linked immunosorbent assay (ELISA) is an extensively used immunologic 
method to detect antigen-antibody binding. The results from different reports 
employing ELISA of anti-IL-17F and anti-IL-22 in APS-I sera were divergent, which 
could possibly reflect both under- and over estimation of the presence of these 
autoantibodies (Paper IV) [86, 256]. As ELISA often depends on commercial 
proteins, the source and the purity of the protein might account for variations in the 
outcome, together with any variations of the secondary antibody used for detection. 
Autoantibodies against IL-22 were identified with higher sensitivity using AVINA 
compared to ELISA, which could reflect a requirement and specificity for naïve 
epitopes [256]. ELISA separated poorly the samples with intermediate AVINA 
results, while the results for the same samples in RIA were consistent with AVINA 
[101]. RIA (Paper II, Paper IV) has the obvious drawback of utilising 35S 
radiolabelled methionine. However, RIA is a reliable method, yielding consistent 
results over time, and is easy to standardise with low inter- and intra- variations, 
which makes it ideal for high-throughput screening.  
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Ethical aspects of autoantibody-screening 
As the cytokine autoantibodies in APS-I (Paper II and Paper IV) are detectable from 
a very early age and before any clinical manifestations [103], they, together with anti-
21-OH, predict a possible onset of disease years before any clinical signs. Therefore, 
they could be suggested as a screening tool in populations with high prevalence of 
inherited autoimmunity, raising ethical questions of population screening. 
 
The importance of autoantibody-screening is exemplified by diabetes type 1, where 
the detection of autoantibodies against islet cell antigens and GAD65 following 
reference standards, are strong predictors of disease [257]. The screening for these 
autoantibodies in different groups including infants, school children and adults aim to 
predict development of the disease and to reveal contribution of environmental 
triggers [258]. In life-threatening but treatable diseases like AAD, type 1 diabetes and 
thyroiditis where autoantibodies precede the clinical symptoms, autoantibody-
screening could be beneficial for the patients and cost saving for the community 
[259]. Yet, as there is no way to avoid progression of these diseases, the risk of over-
treatment and the possible lower quality of life by living with a prospective diagnosis 
should be addressed. 
 
Aire, thymoma, CMC and cytokine autoantibodies 
IFN-, thymoma and AIRE 
We (Paper II) and others [84, 101, 102] have confirmed IFN- as a universal marker 
of APS-I and investigated its diagnostic potential. Interestingly, autoantibodies 
against IFN- and other type-I IFNs were first described in patients with MG and 
thymoma [260], where they are present in sixty per cent of the patients [261].  
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Most human thymomas lack expression of AIRE, but AIRE is still present in the 
remaining tissue of the thymus and in lymph nodes of thymoma-patients, and only 
five per cent develop symptoms characteristic for APS-I [262, 263] (submitted 
manuscript). Forty per cent of the thymoma patients develop MG [264], which is not 
part of the clinical picture seen in APS-I. Interestingly, some thymoma patients also 
display the more common tissue restricted autoantibodies typically seen in APS-I, 
while the reverse is not the case, as anti-Titin and anti-AChR were not found in 
patients with APS-I (submitted manuscript). 
 
The reason why only a few thymoma patients develop an APS-I like clinical picture 
might be due to their normal expression of AIRE in the fetal period, which seems to 
be important in the establishment of tolerance [265], and by their expression of AIRE 
in the periphery and in the residual thymus. This could possibly reflect different roles 
of AIRE throughout life, and support the importance of peripheral tolerance. The 
similarities between the two disorders in terms of cytokine autoantibodies and 
sometimes in clinical picture, indicates a role of AIRE and the thymus in maintaining 
central tolerance even in adult life, and suggest the thymus to be responsible for 
development of the cytokine autoantibodies. Thymoma represent a potential of 
studying the lack of AIRE in thymus in a human setting different from APS-I. 
 
IL-17F, IL-22, thymoma and CMC 
Similar to the autoantibodies against the type-I IFNs, autoantibodies against the Th17 
derived cytokines are a shared feature between APS-I patients with CMC and patients 
with thymoma and CMC. Autoantibodies against IL-17F and IL-22 are reported in 
five to ten per cent of thymoma and CMC patients, and respectively in seventy-five 
and ninety-one per cent of the APS-I patients [256]. In Paper IV, we could not 
confirm these autoantibody-levels, as autoantibodies were detected in thirty-six (anti-
IL-17F) and eighty (anti-IL-22) per cent of the Norwegian APS-I patients. Our results 
from Paper IV indicates a correlation between IL-17F and CMC, and the previous 
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reported correlation between IL-22 and CMC could not be confirmed [85, 256]. Our 
results are more in line with the increased susceptibility to CMC due to impaired IL-
17 immunity in patients with inherited mutations in STAT3, IL-17RA or IL-17 [144-
146]. Conversely, patients with STAT3 mutations have severe staphylococcal 
infection which is not seen in APS-I [266]. Taken together, inefficient signalling, 
autoantibodies targeting the cytokines, or the lack of cytokine expression, all result in 
malfunctions in the Th-17 compartment which predispose for CMC, and the common 
malfunction of the thymus shared between APS-I and thymoma patients is a plausible 
cause for the origin of these autoantibodies. 
Immune cells in APS-I 
The balance between Th17 and Treg cells is of particular interest in the view of 
autoimmunity. Their shared dependence of TGF- is an effective mechanism to 
regulate the effect of the pathogenic Th17 cells [215, 267, 268]. Treg cells were 
shown to be down-regulated in APS-I by us (Paper III) and others [213], and the lack 
of AIRE is suggested as the cause of their impaired suppressive function [214]. Taken 
together, the malfunction of AIRE impairs the function and development of Treg 
cells, making them likely to play a part in the pathogenesis of APS-I. The disrupted 
homeostasis and activation of Treg cells is thought to take place in the periphery due 
to the lack of AIRE [214]. This could be a likely situation, as patients with MG and 
thymoma have normal levels of Treg cells in the periphery, while a decreased number 
Treg cells is found in the residual thymus [269]. However, the status of Treg cells in 
patients with MG and thymoma are still to be established [270-272]. The level of 
CCR4+CCR6+ cells, which includes IL-17A producing cells, were found to be 
unaltered in patients compared to controls (paper III), which is in agreement with the 
unchanged IL-17A response reported in APS-I [85], and isolated CMC [143]. Hence, 
these data emphasise the role of autoantibodies against IL-17F and IL-22 as the main 
mediators of CMC. As the number of Treg and Th17 cells should be balanced, a 
reduced number of Treg cells might imply increase in the levels of Th17 cells. 
However, as we found the levels of Th17 cells in APS-I to be normal (Paper III),  the 
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lack of up-regulation of the Th17 cells could reflect the clinical status of CMC, as 
decreased function and number of Th17 cells are seen in patients with isolated CMC 
[143]. 
 
The number of iNKT cells has previously been reported to be decreased in APS-I 
patients [273], but this finding could not be confirmed in the Norwegian APS-I 
cohort (Paper III). This might be due to the relatively low amounts of iNKT cells in 
blood, which make the data less robust.  
 
The frequency of monocytes in APS-I patients (Paper III) varied between the 
patients, but overall, no significant increases could be detected, as previously 
observed [198, 274]. However, the monocyte sub-population of CD14+CD16+ cells 
was found to be decreased. These monocytes are predicted to inhabit an increased 
APC-activity as they express high levels of HLA-DR [275]. Distribution of high 
doses of methylprednisolone to patients with MS and healthy controls resulted in a 
ninety-five per cent decrease in the levels of CD14+CD16+ cells after five days, 
possibly reflecting selective depletion of these cells by glucocorticoids [276, 277]. 
This could explain the observed decreased frequency, as eighty per cent of our 
patients are diagnosed with AAD and therefore treated with hydrocortisone and 
fludrocortisone. In addition, the levels of CXCR3+CCR6+ Th cells, which co-produce 
IFN- and IL-17A, were reduced in our study, which could reflect the persistent 
CMC infection; increased homing of these cells to inflammatory tissue by binding of 
the interferon-induced chemokine CXCL10 previously shown to be increased in 
APS-I [104], which might decreased their frequency in circulation. 
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Conclusions 
In accordance with the specific aims of this study, the following conclusions can be 
drawn: 
  
• The susceptibility to develop AAD in a Norwegian population was not 
influenced by common polymorphisms in AIRE (Paper I). 
 
• CNV-analysis should be performed in APS-I patients found to be homozygote 
for an AIRE mutation as deletions may be present (Paper I). 
 
• The Norwegian APS-I patients exhibit a reduced number of Treg cells, 
CCR6+CXCR3+ co-expressing Th subpopulation and CD14+CD16+ monocytes 
which may contribute to the observed autoimmunity (Paper III).  
 
• RIA was established as a robust, highly specific method detecting anti-IL17F 
and anti-IL-22 based on monomer or dimers of the interleukins (Paper IV).  
 
• The high prevalence of autoantibodies against IFN- in patients suffering 
from APS-I was confirmed in an expanded cohort of patients from different 
countries including a large number of different controls (Paper II). 
 
• The diagnostic value of IFN- was confirmed in an assay that is easy to 
standardise and ready for high-throughput analysis (Paper II), which is now 
implemented in the routine analysis.  
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Future perspectives 
Patients with APS-I have circulating autoantibodies directed against target enzymes 
in their body, as well as against components of their immune system. As already 
emphasised, these autoantibodies are important markers and predictors of disease. 
Therefore, the identification of additional molecular target within organs or the 
immune system itself is of outmost importance to aid serological diagnosis and may 
shed light on the molecular mechanisms of APS-I. The most widely used, and so far 
most successful method, has been to utilise sera from patients to screen cDNA library 
of different tissues for autoantigens, a method that is well established in our lab. The 
utilisation of more modern techniques, like proteomics, could complement and 
facilitate identification of new autoantigens. 
 
Patients recruited to ROAS are analysed against a panel of different autoantigens, 
which have the potential to be analysed together by the development of new 
immunologic tools. Approaches like flow cytometric bead-based technology or 
peptide arrays have the benefits of reduced sample volumes and allow analysation of 
multiple autoantigens in a single sample, and could also include antigen-markers of 
more common autoimmune endocrine disorders. Using these techniques coupled with 
prospective follow-up of patients could provide new information on the prospective 
value of autoantibody assays. 
 
The underlying cause and function of the autoantibodies remain obscure, and their 
study in patients with APS-I compared to their presence in patients with MG and 
thymoma, might reveal new clues on the pathogenesis of autoimmunity and the 
establishment and maintenance of tolerance. In addition, patients with inherited CMC 
pose an additional human disease with common features which could shed new light 
on immunological pathways.  
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ROAS is still growing, as is the number of APS-I patients included in the registry. 
Among them are several families which potential in studies of the genome and 
proteome as well as cell-based studies are still to be fully exploited.   
 
The role of epigenetic mechanisms and the newly discovered molecular partners of 
AIRE in the thymus pose novel targets to be analysed both in APS-I and in other 
autoimmune diseases. Even though these studies in humans only are possible outside 
the thymus, it should be interesting to investigate the partners of AIRE in different 
autoimmune diseases. Further, to mimic different disease-causing mutations of AIRE 
in cell-culture studies could pinpoint the exact molecular flaw or flaws of nature 
underlying APS-I, with possible implications for explaining the large phenotypic 
variations and severity of the disease. 
 
To date, a combinational approach, utilising autoantibodies and genetic markers is the 
best method to predict the presence and development of APS-I and its components. 
Early diagnosis is crucial, as it gives the opportunity of early intervention, by 
immunomodulation or immunosuppressive treatment. 
  
 65
References  
1. Pietropaolo, M., et al., Primer: immunity and autoimmunity. Diabetes, 2008. 
57(11): p. 2872-82. 
2. Abbas, A.K. and C.A. Janeway, Jr., Immunology: improving on nature in the 
twenty-first century. Cell, 2000. 100(1): p. 129-38. 
3. Iwasaki, A. and R. Medzhitov, Regulation of adaptive immunity by the innate 
immune system. Science, 2010. 327(5963): p. 291-5. 
4. Janeway, C.A., Jr., Approaching the asymptote? Evolution and revolution in 
immunology. Cold Spring Harbor symposia on quantitative biology, 1989. 54 
Pt 1: p. 1-13. 
5. Palm, N.W. and R. Medzhitov, Pattern recognition receptors and control of 
adaptive immunity. Immunological reviews, 2009. 227(1): p. 221-33. 
6. Bernasconi, N.L., E. Traggiai, and A. Lanzavecchia, Maintenance of 
serological memory by polyclonal activation of human memory B cells. 
Science, 2002. 298(5601): p. 2199-202. 
7. Delves, P.J. and I.M. Roitt, The immune system. First of two parts. The New 
England journal of medicine, 2000. 343(1): p. 37-49. 
8. Gay, D., et al., Receptor editing: an approach by autoreactive B cells to 
escape tolerance. The Journal of experimental medicine, 1993. 177(4): p. 999-
1008. 
9. Goodnow, C.C., et al., Altered immunoglobulin expression and functional 
silencing of self-reactive B lymphocytes in transgenic mice. Nature, 1988. 
334(6184): p. 676-82. 
10. Nemazee, D.A. and K. Burki, Clonal deletion of B lymphocytes in a transgenic 
mouse bearing anti-MHC class I antibody genes. Nature, 1989. 337(6207): p. 
562-6. 
11. Radic, M.Z., et al., B lymphocytes may escape tolerance by revising their 
antigen receptors. The Journal of experimental medicine, 1993. 177(4): p. 
1165-73. 
12. Tiegs, S.L., D.M. Russell, and D. Nemazee, Receptor editing in self-reactive 
bone marrow B cells. The Journal of experimental medicine, 1993. 177(4): p. 
1009-20. 
13. Jacobson, B.A., et al., Anatomy of autoantibody production: dominant 
localization of antibody-producing cells to T cell zones in Fas-deficient mice. 
Immunity, 1995. 3(4): p. 509-19. 
14. Van den Eertwegh, A.J., et al., In vivo CD40-gp39 interactions are essential 
for thymus-dependent humoral immunity. I. In vivo expression of CD40 
ligand, cytokines, and antibody production delineates sites of cognate T-B cell 
interactions. The Journal of experimental medicine, 1993. 178(5): p. 1555-65. 
15. Bouaziz, J.D., et al., Therapeutic B cell depletion impairs adaptive and 
autoreactive CD4+ T cell activation in mice. Proceedings of the National 
Academy of Sciences of the United States of America, 2007. 104(52): p. 
20878-83. 
 66
16. DiLillo, D.J., K. Yanaba, and T.F. Tedder, B cells are required for optimal 
CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion 
enhances B16 melanoma growth in mice. Journal of immunology, 2010. 
184(7): p. 4006-16. 
17. DiLillo, D.J., M. Horikawa, and T.F. Tedder, B-lymphocyte effector functions 
in health and disease. Immunologic research, 2011. 49(1-3): p. 281-92. 
18. Mosmann, T.R., et al., Two types of murine helper T cell clone. I. Definition 
according to profiles of lymphokine activities and secreted proteins. J 
Immunol, 1986. 136(7): p. 2348-57. 
19. Iezzi, G., K. Karjalainen, and A. Lanzavecchia, The duration of antigenic 
stimulation determines the fate of naive and effector T cells. Immunity, 1998. 
8(1): p. 89-95. 
20. Murphy, K.M. and B. Stockinger, Effector T cell plasticity: flexibility in the 
face of changing circumstances. Nature immunology, 2010. 11(8): p. 674-80. 
21. Schneider, R., T cells with commitment issues. Science signaling, 2010. 
3(118): p. jc3. 
22. Delves, P.J. and I.M. Roitt, The immune system. Second of two parts. The New 
England journal of medicine, 2000. 343(2): p. 108-17. 
23. Rogge, L., et al., Selective expression of an interleukin-12 receptor component 
by human T helper 1 cells. The Journal of experimental medicine, 1997. 
185(5): p. 825-31. 
24. Szabo, S.J., et al., A novel transcription factor, T-bet, directs Th1 lineage 
commitment. Cell, 2000. 100(6): p. 655-69. 
25. Sallusto, F. and A. Lanzavecchia, Heterogeneity of CD4+ memory T cells: 
functional modules for tailored immunity. European journal of immunology, 
2009. 39(8): p. 2076-82. 
26. Acosta-Rodriguez, E.V., et al., Interleukins 1beta and 6 but not transforming 
growth factor-beta are essential for the differentiation of interleukin 17-
producing human T helper cells. Nature immunology, 2007. 8(9): p. 942-9. 
27. Wilson, N.J., et al., Development, cytokine profile and function of human 
interleukin 17-producing helper T cells. Nature immunology, 2007. 8(9): p. 
950-7. 
28. Ivanov, II, et al., The orphan nuclear receptor RORgammat directs the 
differentiation program of proinflammatory IL-17+ T helper cells. Cell, 2006. 
126(6): p. 1121-33. 
29. Duhen, T., et al., Production of interleukin 22 but not interleukin 17 by a 
subset of human skin-homing memory T cells. Nature immunology, 2009. 
10(8): p. 857-63. 
30. Eyerich, S., et al., Th22 cells represent a distinct human T cell subset involved 
in epidermal immunity and remodeling. J Clin Invest, 2009. 119(12): p. 3573-
85. 
31. Trifari, S., et al., Identification of a human helper T cell population that has 
abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and 
T(H)2 cells. Nat Immunol, 2009. 10(8): p. 864-71. 
 67
32. Hall, B.M., et al., Specific unresponsiveness in rats with prolonged cardiac 
allograft survival after treatment with cyclosporine. III. Further 
characterization of the CD4+ suppressor cell and its mechanisms of action. 
The Journal of experimental medicine, 1990. 171(1): p. 141-57. 
33. Herbelin, A., et al., Mature mainstream TCR alpha beta+CD4+ thymocytes 
expressing L-selectin mediate "active tolerance" in the nonobese diabetic 
mouse. Journal of immunology, 1998. 161(5): p. 2620-8. 
34. Sakaguchi, S., et al., Immunologic self-tolerance maintained by activated T 
cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single 
mechanism of self-tolerance causes various autoimmune diseases. Journal of 
immunology, 1995. 155(3): p. 1151-64. 
35. Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky, Foxp3 programs the 
development and function of CD4+CD25+ regulatory T cells. Nature 
immunology, 2003. 4(4): p. 330-6. 
36. Hori, S., T. Nomura, and S. Sakaguchi, Control of regulatory T cell 
development by the transcription factor Foxp3. Science, 2003. 299(5609): p. 
1057-61. 
37. Khattri, R., et al., An essential role for Scurfin in CD4+CD25+ T regulatory 
cells. Nature immunology, 2003. 4(4): p. 337-42. 
38. Novak, J. and A. Lehuen, Mechanism of regulation of autoimmunity by iNKT 
cells. Cytokine, 2011. 53(3): p. 263-70. 
39. Alonzo, E.S. and D.B. Sant'Angelo, Development of PLZF-expressing innate 
T cells. Current opinion in immunology, 2011. 23(2): p. 220-7. 
40. Jacobson, D.L., et al., Epidemiology and estimated population burden of 
selected autoimmune diseases in the United States. Clin Immunol 
Immunopathol, 1997. 84(3): p. 223-43. 
41. Anderson, M.S., Update in endocrine autoimmunity. J Clin Endocrinol Metab, 
2008. 93(10): p. 3663-70. 
42. Dabelea, D., et al., Incidence of diabetes in youth in the United States. JAMA : 
the journal of the American Medical Association, 2007. 297(24): p. 2716-24. 
43. Harjutsalo, V., L. Sjoberg, and J. Tuomilehto, Time trends in the incidence of 
type 1 diabetes in Finnish children: a cohort study. Lancet, 2008. 371(9626): 
p. 1777-82. 
44. Bach, J.F., The effect of infections on susceptibility to autoimmune and 
allergic diseases. N Engl J Med, 2002. 347(12): p. 911-20. 
45. Anderson, M.S., Autoimmune endocrine disease. Curr Opin Immunol, 2002. 
14(6): p. 760-4. 
46. Wolff, A.S., et al., Autoimmune polyendocrine syndrome type 1 in Norway: 
phenotypic variation, autoantibodies, and novel mutations in the autoimmune 
regulator gene. J Clin Endocrinol Metab, 2007. 92(2): p. 595-603. 
47. Betterle, C., N.A. Greggio, and M. Volpato, Clinical review 93: Autoimmune 
polyglandular syndrome type 1. J Clin Endocrinol Metab, 1998. 83(4): p. 
1049-55. 
 68
48. Ahonen, P., et al., Clinical variation of autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N 
Engl J Med, 1990. 322(26): p. 1829-36. 
49. Perheentupa, J., Autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy. J Clin Endocrinol Metab, 2006. 91(8): p. 2843-50. 
50. Husebye, E.S., et al., Clinical manifestations and management of patients with 
autoimmune polyendocrine syndrome type I. J Intern Med, 2009. 265(5): p. 
514-29. 
51. Gass, J.D., The syndrome of keratoconjunctivitis, superficial moniliasis, 
idiopathic hypoparathyroidism and Addison's disease. American journal of 
ophthalmology, 1962. 54: p. 660-74. 
52. Rautemaa, R., et al., Oral and oesophageal squamous cell carcinoma--a 
complication or component of autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED, APS-I). Oral Oncol, 2007. 43(6): p. 607-13. 
53. Myhre, A.G., et al., Autoimmune polyendocrine syndrome type 1 (APS I) in 
Norway. Clinical endocrinology, 2001. 54(2): p. 211-7. 
54. Gylling, M., et al., The hypoparathyroidism of autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy protective effect of 
male sex. The Journal of clinical endocrinology and metabolism, 2003. 88(10): 
p. 4602-8. 
55. Alimohammadi, M., et al., Autoimmune polyendocrine syndrome type 1 and 
NALP5, a parathyroid autoantigen. N Engl J Med, 2008. 358(10): p. 1018-28. 
56. Addison, T., On the constitutional and local effects of disease of the 
suprarenal capsules., in London: Samuel Highley1855. 
57. Soderbergh, A., et al., Prevalence and clinical associations of 10 defined 
autoantibodies in autoimmune polyendocrine syndrome type I. J Clin 
Endocrinol Metab, 2004. 89(2): p. 557-62. 
58. Winqvist, O., F.A. Karlsson, and O. Kampe, 21-Hydroxylase, a major 
autoantigen in idiopathic Addison's disease. Lancet, 1992. 339(8809): p. 
1559-62. 
59. Lovas, K. and E.S. Husebye, Addison's disease. Lancet, 2005. 365(9476): p. 
2058-61. 
60. Erichsen, M.M., et al., Normal overall mortality rate in Addison's disease, but 
young patients are at risk of premature death. European journal of 
endocrinology / European Federation of Endocrine Societies, 2009. 160(2): p. 
233-7. 
61. Eisenbarth, G.S. and P.A. Gottlieb, Autoimmune polyendocrine syndromes. N 
Engl J Med, 2004. 350(20): p. 2068-79. 
62. Betterle, C., et al., Autoimmune adrenal insufficiency and autoimmune 
polyendocrine syndromes: autoantibodies, autoantigens, and their 
applicability in diagnosis and disease prediction. Endocr Rev, 2002. 23(3): p. 
327-64. 
63. Falorni, A., et al., 21-hydroxylase autoantibodies in adult patients with 
endocrine autoimmune diseases are highly specific for Addison's disease. 
Belgian Diabetes Registry. Clin Exp Immunol, 1997. 107(2): p. 341-6. 
 69
64. Peterson, P., et al., Immunoprecipitation of steroidogenic enzyme autoantigens 
with autoimmune polyglandular syndrome type I (APS I) sera; further 
evidence for independent humoral immunity to P450c17 and P450c21. Clin 
Exp Immunol, 1997. 107(2): p. 335-40. 
65. Uibo, R., et al., Autoantibodies to cytochrome P450 enzymes P450scc, 
P450c17, and P450c21 in autoimmune polyglandular disease types I and II 
and in isolated Addison's disease. J Clin Endocrinol Metab, 1994. 78(2): p. 
323-8. 
66. Winqvist, O., et al., Two different cytochrome P450 enzymes are the adrenal 
antigens in autoimmune polyendocrine syndrome type I and Addison's disease. 
The Journal of clinical investigation, 1993. 92(5): p. 2377-85. 
67. Krohn, K., et al., Identification by molecular cloning of an autoantigen 
associated with Addison's disease as steroid 17 alpha-hydroxylase. Lancet, 
1992. 339(8796): p. 770-3. 
68. Velloso, L.A., et al., Autoantibodies against a novel 51 kDa islet antigen and 
glutamate decarboxylase isoforms in autoimmune polyendocrine syndrome 
type I. Diabetologia, 1994. 37(1): p. 61-9. 
69. Clemente, M.G., et al., Cytochrome P450 1A2 is a hepatic autoantigen in 
autoimmune polyglandular syndrome type 1. The Journal of clinical 
endocrinology and metabolism, 1997. 82(5): p. 1353-61. 
70. Husebye, E.S., et al., Autoantibodies against aromatic L-amino acid 
decarboxylase in autoimmune polyendocrine syndrome type I. J Clin 
Endocrinol Metab, 1997. 82(1): p. 147-50. 
71. Ekwall, O., et al., Identification of tryptophan hydroxylase as an intestinal 
autoantigen. Lancet, 1998. 352(9124): p. 279-83. 
72. Hedstrand, H., et al., Antibodies against hair follicles are associated with 
alopecia totalis in autoimmune polyendocrine syndrome type I. The Journal of 
investigative dermatology, 1999. 113(6): p. 1054-8. 
73. Winqvist, O., et al., Identification of the main gonadal autoantigens in patients 
with adrenal insufficiency and associated ovarian failure. J Clin Endocrinol 
Metab, 1995. 80(5): p. 1717-23. 
74. Betterle, C., et al., Adrenal-cortex autoantibodies and steroid-producing cells 
autoantibodies in patients with Addison's disease: comparison of 
immunofluorescence and immunoprecipitation assays. The Journal of clinical 
endocrinology and metabolism, 1999. 84(2): p. 618-22. 
75. Chen, S., et al., Autoantibodies to steroidogenic enzymes in autoimmune 
polyglandular syndrome, Addison's disease, and premature ovarian failure. 
The Journal of clinical endocrinology and metabolism, 1996. 81(5): p. 1871-6. 
76. Dal Pra, C., et al., Autoantibodies to human tryptophan hydroxylase and 
aromatic L-amino acid decarboxylase. European journal of endocrinology / 
European Federation of Endocrine Societies, 2004. 150(3): p. 313-21. 
77. Ekwall, O., et al., Tryptophan hydroxylase autoantibodies and intestinal 
disease in autoimmune polyendocrine syndrome type 1. Lancet, 1999. 
354(9178): p. 568. 
 70
78. Kemp, E.H., et al., Autoantibodies against tyrosine hydroxylase in patients 
with non-segmental (generalised) vitiligo. Experimental dermatology, 2011. 
20(1): p. 35-40. 
79. Kemp, E.H., et al., Demonstration of autoantibodies against tyrosine 
hydroxylase in patients with alopecia areata. The British journal of 
dermatology, 2011. 
80. Baekkeskov, S., et al., Identification of the 64K autoantigen in insulin-
dependent diabetes as the GABA-synthesizing enzyme glutamic acid 
decarboxylase. Nature, 1990. 347(6289): p. 151-6. 
81. Li, Y., et al., Autoantibodies to the extracellular domain of the calcium 
sensing receptor in patients with acquired hypoparathyroidism. The Journal of 
clinical investigation, 1996. 97(4): p. 910-4. 
82. Gavalas, N.G., et al., The calcium-sensing receptor is a target of 
autoantibodies in patients with autoimmune polyendocrine syndrome type 1. 
The Journal of clinical endocrinology and metabolism, 2007. 92(6): p. 2107-
14. 
83. Kemp, E.H., et al., Activating autoantibodies against the calcium-sensing 
receptor detected in two patients with autoimmune polyendocrine syndrome 
type 1. The Journal of clinical endocrinology and metabolism, 2009. 94(12): p. 
4749-56. 
84. Meager, A., et al., Anti-interferon autoantibodies in autoimmune 
polyendocrinopathy syndrome type 1. PLoS Med, 2006. 3(7): p. e289. 
85. Kisand, K., et al., Chronic mucocutaneous candidiasis in APECED or 
thymoma patients correlates with autoimmunity to Th17-associated cytokines. 
J Exp Med. 207(2): p. 299-308. 
86. Puel, A., et al., Autoantibodies against IL-17A, IL-17F, and IL-22 in patients 
with chronic mucocutaneous candidiasis and autoimmune polyendocrine 
syndrome type I. J Exp Med. 207(2): p. 291-7. 
87. Isaacs, A. and J. Lindenmann, Virus interference. I. The interferon. Proc R Soc 
Lond B Biol Sci, 1957. 147(927): p. 258-67. 
88. Hertzog, P.J., L.A. O'Neill, and J.A. Hamilton, The interferon in TLR 
signaling: more than just antiviral. Trends Immunol, 2003. 24(10): p. 534-9. 
89. Pestka, S., C.D. Krause, and M.R. Walter, Interferons, interferon-like 
cytokines, and their receptors. Immunol Rev, 2004. 202: p. 8-32. 
90. Benveniste, E.N. and H. Qin, Type I interferons as anti-inflammatory 
mediators. Sci STKE, 2007. 2007(416): p. pe70. 
91. Billiau, A., Anti-inflammatory properties of Type I interferons. Antiviral Res, 
2006. 71(2-3): p. 108-16. 
92. Tak, P.P., IFN-beta in rheumatoid arthritis. Front Biosci, 2004. 9: p. 3242-7. 
93. Banchereau, J. and V. Pascual, Type I interferon in systemic lupus 
erythematosus and other autoimmune diseases. Immunity, 2006. 25(3): p. 
383-92. 
94. Buttmann, M. and P. Rieckmann, Interferon-beta1b in multiple sclerosis. 
Expert Rev Neurother, 2007. 7(3): p. 227-39. 
 71
95. Shiono, H., et al., Spontaneous production of anti-IFN-alpha and anti-IL-12 
autoantibodies by thymoma cells from myasthenia gravis patients suggests 
autoimmunization in the tumor. Int Immunol, 2003. 15(8): p. 903-13. 
96. Romi, F., Thymoma in myasthenia gravis: from diagnosis to treatment. 
Autoimmune diseases, 2011. 2011: p. 474512. 
97. Bleul, C.C., et al., Formation of a functional thymus initiated by a postnatal 
epithelial progenitor cell. Nature, 2006. 441(7096): p. 992-6. 
98. Rodewald, H.R., et al., Thymus medulla consisting of epithelial islets each 
derived from a single progenitor. Nature, 2001. 414(6865): p. 763-8. 
99. Rossi, S.W., et al., Clonal analysis reveals a common progenitor for thymic 
cortical and medullary epithelium. Nature, 2006. 441(7096): p. 988-91. 
100. Shakib, S., et al., Checkpoints in the development of thymic cortical epithelial 
cells. J Immunol, 2009. 182(1): p. 130-7. 
101. Meloni, A., et al., Autoantibodies against type I interferons as an additional 
diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin 
Endocrinol Metab, 2008. 93(11): p. 4389-97. 
102. Zhang, L., et al., A robust immunoassay for anti-interferon autoantibodies that 
is highly specific for patients with autoimmune polyglandular syndrome type 
1. Clin Immunol, 2007. 125(2): p. 131-7. 
103. Toth, B., et al., Novel sequence variation of AIRE and detection of interferon-
omega antibodies in early infancy. Clinical endocrinology, 2010. 72(5): p. 
641-7. 
104. Kisand, K., et al., Interferon autoantibodies associated with AIRE deficiency 
decrease the expression of IFN-stimulated genes. Blood, 2008. 112(7): p. 
2657-66. 
105. Harrington, L.E., et al., Interleukin 17-producing CD4+ effector T cells 
develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat 
Immunol, 2005. 6(11): p. 1123-32. 
106. Fossiez, F., et al., T cell interleukin-17 induces stromal cells to produce 
proinflammatory and hematopoietic cytokines. J Exp Med, 1996. 183(6): p. 
2593-603. 
107. Hymowitz, S.G., et al., IL-17s adopt a cystine knot fold: structure and activity 
of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J, 
2001. 20(19): p. 5332-41. 
108. Li, H., et al., Cloning and characterization of IL-17B and IL-17C, two new 
members of the IL-17 cytokine family. Proc Natl Acad Sci U S A, 2000. 97(2): 
p. 773-8. 
109. Starnes, T., et al., Cutting edge: IL-17D, a novel member of the IL-17 family, 
stimulates cytokine production and inhibits hemopoiesis. J Immunol, 2002. 
169(2): p. 642-6. 
110. Dumoutier, L., J. Louahed, and J.C. Renauld, Cloning and characterization of 
IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine 
structurally related to IL-10 and inducible by IL-9. J Immunol, 2000. 164(4): 
p. 1814-9. 
 72
111. Xie, M.H., et al., Interleukin (IL)-22, a novel human cytokine that signals 
through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol 
Chem, 2000. 275(40): p. 31335-9. 
112. Acosta-Rodriguez, E.V., et al., Surface phenotype and antigenic specificity of 
human interleukin 17-producing T helper memory cells. Nat Immunol, 2007. 
8(6): p. 639-46. 
113. Cosmi, L., et al., Human interleukin 17-producing cells originate from a 
CD161+CD4+ T cell precursor. J Exp Med, 2008. 205(8): p. 1903-16. 
114. Kleinschek, M.A., et al., Circulating and gut-resident human Th17 cells 
express CD161 and promote intestinal inflammation. J Exp Med, 2009. 
206(3): p. 525-34. 
115. Rachitskaya, A.V., et al., Cutting edge: NKT cells constitutively express IL-23 
receptor and RORgammat and rapidly produce IL-17 upon receptor ligation 
in an IL-6-independent fashion. J Immunol, 2008. 180(8): p. 5167-71. 
116. Colonna, M., Interleukin-22-producing natural killer cells and lymphoid tissue 
inducer-like cells in mucosal immunity. Immunity, 2009. 31(1): p. 15-23. 
117. Takatori, H., et al., Lymphoid tissue inducer-like cells are an innate source of 
IL-17 and IL-22. The Journal of experimental medicine, 2009. 206(1): p. 35-
41. 
118. Cupedo, T., et al., Human fetal lymphoid tissue-inducer cells are interleukin 
17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat 
Immunol, 2009. 10(1): p. 66-74. 
119. Crellin, N.K., et al., Human NKp44+IL-22+ cells and LTi-like cells constitute 
a stable RORC+ lineage distinct from conventional natural killer cells. J Exp 
Med. 207(2): p. 281-90. 
120. Cella, M., et al., A human natural killer cell subset provides an innate source 
of IL-22 for mucosal immunity. Nature, 2009. 457(7230): p. 722-5. 
121. Eyerich, S., et al., IL-17 and IL-22: siblings, not twins. Trends in immunology, 
2010. 31(9): p. 354-61. 
122. Wright, J.F., et al., Identification of an interleukin 17F/17A heterodimer in 
activated human CD4+ T cells. J Biol Chem, 2007. 282(18): p. 13447-55. 
123. Wright, J.F., et al., The human IL-17F/IL-17A heterodimeric cytokine signals 
through the IL-17RA/IL-17RC receptor complex. J Immunol, 2008. 181(4): p. 
2799-805. 
124. Awane, M., et al., NF-kappa B-inducing kinase is a common mediator of IL-
17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in 
intestinal epithelial cells. J Immunol, 1999. 162(9): p. 5337-44. 
125. Kawaguchi, M., L.F. Onuchic, and S.K. Huang, Activation of extracellular 
signal-regulated kinase (ERK)1/2, but not p38 and c-Jun N-terminal kinase, is 
involved in signaling of a novel cytokine, ML-1. J Biol Chem, 2002. 277(18): 
p. 15229-32. 
126. Laan, M., et al., IL-17-induced cytokine release in human bronchial epithelial 
cells in vitro: role of mitogen-activated protein (MAP) kinases. Br J 
Pharmacol, 2001. 133(1): p. 200-6. 
 73
127. Onishi, R.M. and S.L. Gaffen, Interleukin-17 and its target genes: 
mechanisms of interleukin-17 function in disease. Immunology. 129(3): p. 
311-21. 
128. Da Silva, C.A., et al., TLR-2 and IL-17A in chitin-induced macrophage 
activation and acute inflammation. Journal of immunology, 2008. 181(6): p. 
4279-86. 
129. Hou, W., H.S. Kang, and B.S. Kim, Th17 cells enhance viral persistence and 
inhibit T cell cytotoxicity in a model of chronic virus infection. The Journal of 
experimental medicine, 2009. 206(2): p. 313-28. 
130. Ishigame, H., et al., Differential roles of interleukin-17A and -17F in host 
defense against mucoepithelial bacterial infection and allergic responses. 
Immunity, 2009. 30(1): p. 108-19. 
131. Silva, W.A., Jr., et al., The profile of gene expression of human marrow 
mesenchymal stem cells. Stem cells, 2003. 21(6): p. 661-9. 
132. Haudenschild, D., et al., Soluble and transmembrane isoforms of novel 
interleukin-17 receptor-like protein by RNA splicing and expression in 
prostate cancer. The Journal of biological chemistry, 2002. 277(6): p. 4309-
16. 
133. Moseley, T.A., et al., Interleukin-17 family and IL-17 receptors. Cytokine & 
growth factor reviews, 2003. 14(2): p. 155-74. 
134. Nograles, K.E., et al., Th17 cytokines interleukin (IL)-17 and IL-22 modulate 
distinct inflammatory and keratinocyte-response pathways. Br J Dermatol, 
2008. 159(5): p. 1092-102. 
135. de Oliveira Neto, M., et al., Interleukin-22 forms dimers that are recognized 
by two interleukin-22R1 receptor chains. Biophys J, 2008. 94(5): p. 1754-65. 
136. Wolk, K., et al., IL-22 increases the innate immunity of tissues. Immunity, 
2004. 21(2): p. 241-54. 
137. Dhiman, R., et al., IL-22 produced by human NK cells inhibits growth of 
Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol, 
2009. 183(10): p. 6639-45. 
138. Andoh, A., et al., Interleukin-22, a member of the IL-10 subfamily, induces 
inflammatory responses in colonic subepithelial myofibroblasts. 
Gastroenterology, 2005. 129(3): p. 969-84. 
139. Ikeuchi, H., et al., Expression of interleukin-22 in rheumatoid arthritis: 
potential role as a proinflammatory cytokine. Arthritis Rheum, 2005. 52(4): p. 
1037-46. 
140. Wolk, K., et al., IL-22 regulates the expression of genes responsible for 
antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a 
potential role in psoriasis. Eur J Immunol, 2006. 36(5): p. 1309-23. 
141. Boniface, K., et al., IL-22 inhibits epidermal differentiation and induces 
proinflammatory gene expression and migration of human keratinocytes. 
Journal of immunology, 2005. 174(6): p. 3695-702. 
142. Radaeva, S., et al., Interleukin 22 (IL-22) plays a protective role in T cell-
mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via 
STAT3 activation. Hepatology, 2004. 39(5): p. 1332-42. 
 74
143. Eyerich, K., et al., Patients with chronic mucocutaneous candidiasis exhibit 
reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest 
Dermatol, 2008. 128(11): p. 2640-5. 
144. Milner, J.D., et al., Impaired T(H)17 cell differentiation in subjects with 
autosomal dominant hyper-IgE syndrome. Nature, 2008. 452(7188): p. 773-6. 
145. Yang, X.O., et al., STAT3 regulates cytokine-mediated generation of 
inflammatory helper T cells. The Journal of biological chemistry, 2007. 
282(13): p. 9358-63. 
146. Puel, A., et al., Chronic mucocutaneous candidiasis in humans with inborn 
errors of interleukin-17 immunity. Science, 2011. 332(6025): p. 65-8. 
147. Eyerich, S., et al., IL-22 and TNF-alpha represent a key cytokine combination 
for epidermal integrity during infection with Candida albicans. European 
journal of immunology, 2011. 41(7): p. 1894-901. 
148. Feng, Z., et al., Human beta-defensins: differential activity against candidal 
species and regulation by Candida albicans. Journal of dental research, 2005. 
84(5): p. 445-50. 
149. Cheng, F., et al., Decreased plasma IL22 levels, but not increased IL17 and 
IL23 levels, correlate with disease activity in patients with systemic lupus 
erythematosus. Ann Rheum Dis, 2009. 68(4): p. 604-6. 
150. Pan, H.F., et al., Decreased serum IL-22 levels in patients with systemic lupus 
erythematosus. Clin Chim Acta, 2009. 401(1-2): p. 179-80. 
151. Brand, S., et al., IL-22 is increased in active Crohn's disease and promotes 
proinflammatory gene expression and intestinal epithelial cell migration. Am 
J Physiol Gastrointest Liver Physiol, 2006. 290(4): p. G827-38. 
152. Ahlgren, K.M., et al., Increased IL-17A secretion in response to Candida 
albicans in autoimmune polyendocrine syndrome type 1 and its animal model. 
Eur J Immunol. 
153. An autoimmune disease, APECED, caused by mutations in a novel gene 
featuring two PHD-type zinc-finger domains. Nat Genet, 1997. 17(4): p. 399-
403. 
154. Nagamine, K., et al., Positional cloning of the APECED gene. Nat Genet, 
1997. 17(4): p. 393-8. 
155. Aaltonen, J., et al., An autosomal locus causing autoimmune disease: 
autoimmune polyglandular disease type I assigned to chromosome 21. Nature 
genetics, 1994. 8(1): p. 83-7. 
156. Cetani, F., et al., A novel mutation of the autoimmune regulator gene in an 
Italian kindred with autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy, acting in a dominant fashion and strongly cosegregating with 
hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab, 2001. 86(10): 
p. 4747-52. 
157. Husebye, E.S. and M.S. Anderson, Autoimmune polyendocrine syndromes: 
clues to type 1 diabetes pathogenesis. Immunity. 32(4): p. 479-87. 
158. Vogel, A., et al., The genetic background of autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy and its autoimmune disease components. 
Journal of molecular medicine, 2002. 80(4): p. 201-11. 
 75
159. Zlotogora, J. and M.S. Shapiro, Polyglandular autoimmune syndrome type I 
among Iranian Jews. Journal of medical genetics, 1992. 29(11): p. 824-6. 
160. Bjorses, P., et al., Localization of the APECED protein in distinct nuclear 
structures. Hum Mol Genet, 1999. 8(2): p. 259-66. 
161. Heino, M., et al., Autoimmune regulator is expressed in the cells regulating 
immune tolerance in thymus medulla. Biochem Biophys Res Commun, 1999. 
257(3): p. 821-5. 
162. Rinderle, C., et al., AIRE encodes a nuclear protein co-localizing with 
cytoskeletal filaments: altered sub-cellular distribution of mutants lacking the 
PHD zinc fingers. Hum Mol Genet, 1999. 8(2): p. 277-90. 
163. Derbinski, J., et al., Promiscuous gene expression in medullary thymic 
epithelial cells mirrors the peripheral self. Nat Immunol, 2001. 2(11): p. 1032-
9. 
164. Zuklys, S., et al., Normal thymic architecture and negative selection are 
associated with Aire expression, the gene defective in the autoimmune-
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J 
Immunol, 2000. 165(4): p. 1976-83. 
165. Poliani, P.L., et al., Human peripheral lymphoid tissues contain autoimmune 
regulator-expressing dendritic cells. The American journal of pathology, 
2010. 176(3): p. 1104-12. 
166. Suzuki, E., et al., Expression of AIRE in thymocytes and peripheral 
lymphocytes. Autoimmunity, 2008. 41(2): p. 133-9. 
167. Pontynen, N., et al., Critical immunological pathways are downregulated in 
APECED patient dendritic cells. Journal of molecular medicine, 2008. 86(10): 
p. 1139-52. 
168. Eldershaw, S.A., D.M. Sansom, and P. Narendran, Expression and function of 
the autoimmune regulator (Aire) gene in non-thymic tissue. Clinical and 
experimental immunology, 2011. 163(3): p. 296-308. 
169. Heino, M., et al., RNA and protein expression of the murine autoimmune 
regulator gene (Aire) in normal, RelB-deficient and in NOD mouse. Eur J 
Immunol, 2000. 30(7): p. 1884-93. 
170. Ruan, Q.G., et al., Expression and alternative splicing of the mouse 
autoimmune regulator gene (Aire). Journal of autoimmunity, 1999. 13(3): p. 
307-13. 
171. Schaller, C.E., et al., Expression of Aire and the early wave of apoptosis in 
spermatogenesis. Journal of immunology, 2008. 180(3): p. 1338-43. 
172. Zheng, X., et al., Expression of tissue-specific autoantigens in the 
hematopoietic cells leads to activation-induced cell death of autoreactive T 
cells in the secondary lymphoid organs. European journal of immunology, 
2004. 34(11): p. 3126-34. 
173. Halonen, M., et al., Subcellular location and expression pattern of 
autoimmune regulator (Aire), the mouse orthologue for human gene defective 
in autoimmune polyendocrinopathy candidiasis ectodermal dystrophy 
(APECED). The journal of histochemistry and cytochemistry : official journal 
of the Histochemistry Society, 2001. 49(2): p. 197-208. 
 76
174. Gardner, J.M., et al., Deletional tolerance mediated by extrathymic Aire-
expressing cells. Science, 2008. 321(5890): p. 843-7. 
175. Hubert, F.X., et al., A specific anti-Aire antibody reveals aire expression is 
restricted to medullary thymic epithelial cells and not expressed in periphery. 
Journal of immunology, 2008. 180(6): p. 3824-32. 
176. Ramsey, C., et al., Aire deficient mice develop multiple features of APECED 
phenotype and show altered immune response. Human molecular genetics, 
2002. 11(4): p. 397-409. 
177. Gibson, T.J., et al., The APECED polyglandular autoimmune syndrome 
protein, AIRE-1, contains the SAND domain and is probably a transcription 
factor. Trends Biochem Sci, 1998. 23(7): p. 242-4. 
178. Ferguson, B.J., et al., AIRE's CARD revealed, a new structure for central 
tolerance provokes transcriptional plasticity. J Biol Chem, 2008. 283(3): p. 
1723-31. 
179. Purohit, S., et al., Mapping DNA-binding domains of the autoimmune 
regulator protein. Biochem Biophys Res Commun, 2005. 327(3): p. 939-44. 
180. Bjorses, P., et al., Mutations in the AIRE gene: effects on subcellular location 
and transactivation function of the autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy protein. Am J Hum Genet, 2000. 66(2): p. 
378-92. 
181. Pitkanen, J., et al., The autoimmune regulator protein has transcriptional 
transactivating properties and interacts with the common coactivator CREB-
binding protein. J Biol Chem, 2000. 275(22): p. 16802-9. 
182. Kumar, P.G., et al., The autoimmune regulator (AIRE) is a DNA-binding 
protein. The Journal of biological chemistry, 2001. 276(44): p. 41357-64. 
183. Peterson, P., T. Org, and A. Rebane, Transcriptional regulation by AIRE: 
molecular mechanisms of central tolerance. Nature reviews. Immunology, 
2008. 8(12): p. 948-57. 
184. Blechschmidt, K., et al., The mouse Aire gene: comparative genomic 
sequencing, gene organization, and expression. Genome Res, 1999. 9(2): p. 
158-66. 
185. Mittaz, L., et al., Isolation and characterization of the mouse Aire gene. 
Biochem Biophys Res Commun, 1999. 255(2): p. 483-90. 
186. Wang, C.Y., et al., Cloning of Aire, the mouse homologue of the autoimmune 
regulator (AIRE) gene responsible for autoimmune polyglandular syndrome 
type 1 (ASP1). Genomics, 1999. 55(3): p. 322-6. 
187. Ruan, Q.G., et al., The autoimmune regulator directly controls the expression 
of genes critical for thymic epithelial function. J Immunol, 2007. 178(11): p. 
7173-80. 
188. Takahama, Y., Journey through the thymus: stromal guides for T-cell 
development and selection. Nat Rev Immunol, 2006. 6(2): p. 127-35. 
189. Metzger, T.C. and M.S. Anderson, Control of central and peripheral tolerance 
by Aire. Immunological reviews, 2011. 241(1): p. 89-103. 
 77
190. Gotter, J., et al., Medullary epithelial cells of the human thymus express a 
highly diverse selection of tissue-specific genes colocalized in chromosomal 
clusters. J Exp Med, 2004. 199(2): p. 155-66. 
191. Anderson, M.S., et al., Projection of an immunological self shadow within the 
thymus by the aire protein. Science, 2002. 298(5597): p. 1395-401. 
192. Derbinski, J., et al., Promiscuous gene expression in thymic epithelial cells is 
regulated at multiple levels. J Exp Med, 2005. 202(1): p. 33-45. 
193. Tykocinski, L.O., et al., Epigenetic regulation of promiscuous gene expression 
in thymic medullary epithelial cells. Proc Natl Acad Sci U S A. 107(45): p. 
19426-31. 
194. Liston, A., et al., Gene dosage--limiting role of Aire in thymic expression, 
clonal deletion, and organ-specific autoimmunity. J Exp Med, 2004. 200(8): p. 
1015-26. 
195. Abramson, J., et al., Aire's partners in the molecular control of immunological 
tolerance. Cell. 140(1): p. 123-35. 
196. Koh, A.S., et al., Aire employs a histone-binding module to mediate 
immunological tolerance, linking chromatin regulation with organ-specific 
autoimmunity. Proc Natl Acad Sci U S A, 2008. 105(41): p. 15878-83. 
197. Org, T., et al., AIRE activated tissue specific genes have histone modifications 
associated with inactive chromatin. Human molecular genetics, 2009. 18(24): 
p. 4699-710. 
198. Hong, M., et al., Pattern recognition receptor expression is not impaired in 
patients with chronic mucocutanous candidiasis with or without autoimmune 
polyendocrinopathy candidiasis ectodermal dystrophy. Clinical and 
experimental immunology, 2009. 156(1): p. 40-51. 
199. Anderson, M.S., et al., The cellular mechanism of Aire control of T cell 
tolerance. Immunity, 2005. 23(2): p. 227-39. 
200. Gray, D., et al., Proliferative arrest and rapid turnover of thymic epithelial 
cells expressing Aire. The Journal of experimental medicine, 2007. 204(11): p. 
2521-8. 
201. Hubert, F.X., et al., Aire regulates the transfer of antigen from mTECs to 
dendritic cells for induction of thymic tolerance. Blood, 2011. 118(9): p. 2462-
72. 
202. Hernandez, J., et al., Phenotypic and functional analysis of CD8(+) T cells 
undergoing peripheral deletion in response to cross-presentation of self-
antigen. J Exp Med, 2001. 194(6): p. 707-17. 
203. Kurts, C., et al., Class I-restricted cross-presentation of exogenous self-
antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med, 1997. 
186(2): p. 239-45. 
204. Liu, Z. and L. Lefrancois, Intestinal epithelial antigen induces mucosal CD8 T 
cell tolerance, activation, and inflammatory response. J Immunol, 2004. 
173(7): p. 4324-30. 
205. Redmond, W.L., B.C. Marincek, and L.A. Sherman, Distinct requirements for 
deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J 
Immunol, 2005. 174(4): p. 2046-53. 
 78
206. Weninger, W., et al., Naive T cell recruitment to nonlymphoid tissues: a role 
for endothelium-expressed CC chemokine ligand 21 in autoimmune disease 
and lymphoid neogenesis. Journal of immunology, 2003. 170(9): p. 4638-48. 
207. Fletcher, A.L., et al., Lymph node fibroblastic reticular cells directly present 
peripheral tissue antigen under steady-state and inflammatory conditions. The 
Journal of experimental medicine, 2010. 207(4): p. 689-97. 
208. Lee, J.W., et al., Peripheral antigen display by lymph node stroma promotes T 
cell tolerance to intestinal self. Nature immunology, 2007. 8(2): p. 181-90. 
209. Tang, Q. and J.A. Bluestone, The Foxp3+ regulatory T cell: a jack of all 
trades, master of regulation. Nature immunology, 2008. 9(3): p. 239-44. 
210. Costantino, C.M., C.M. Baecher-Allan, and D.A. Hafler, Human regulatory T 
cells and autoimmunity. European journal of immunology, 2008. 38(4): p. 
921-4. 
211. Gambineri, E., T.R. Torgerson, and H.D. Ochs, Immune dysregulation, 
polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a 
syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical 
regulator of T-cell homeostasis. Current opinion in rheumatology, 2003. 
15(4): p. 430-5. 
212. Bluestone, J.A., Regulatory T-cell therapy: is it ready for the clinic? Nature 
reviews. Immunology, 2005. 5(4): p. 343-9. 
213. Kekalainen, E., et al., A defect of regulatory T cells in patients with 
autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Journal 
of immunology, 2007. 178(2): p. 1208-15. 
214. Laakso, S.M., et al., Regulatory T cell defect in APECED patients is 
associated with loss of naive FOXP3(+) precursors and impaired activated 
population. Journal of autoimmunity, 2010. 35(4): p. 351-7. 
215. Bettelli, E., et al., Reciprocal developmental pathways for the generation of 
pathogenic effector TH17 and regulatory T cells. Nature, 2006. 441(7090): p. 
235-8. 
216. Mucida, D., et al., Reciprocal TH17 and regulatory T cell differentiation 
mediated by retinoic acid. Science, 2007. 317(5835): p. 256-60. 
217. Laurence, A., et al., Interleukin-2 signaling via STAT5 constrains T helper 17 
cell generation. Immunity, 2007. 26(3): p. 371-81. 
218. Du, J., et al., Isoform-specific inhibition of ROR alpha-mediated 
transcriptional activation by human FOXP3. Journal of immunology, 2008. 
180(7): p. 4785-92. 
219. Zhou, L., et al., TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation 
by antagonizing RORgammat function. Nature, 2008. 453(7192): p. 236-40. 
220. Zhou, L., M.M. Chong, and D.R. Littman, Plasticity of CD4+ T cell lineage 
differentiation. Immunity, 2009. 30(5): p. 646-55. 
221. Zhou, X., et al., Instability of the transcription factor Foxp3 leads to the 
generation of pathogenic memory T cells in vivo. Nature immunology, 2009. 
10(9): p. 1000-7. 
222. DeVoss, J.J. and M.S. Anderson, Lessons on immune tolerance from the 
monogenic disease APS1. Curr Opin Genet Dev, 2007. 17(3): p. 193-200. 
 79
223. Pugliese, A., et al., The insulin gene is transcribed in the human thymus and 
transcription levels correlated with allelic variation at the INS VNTR-IDDM2 
susceptibility locus for type 1 diabetes. Nat Genet, 1997. 15(3): p. 293-7. 
224. Vafiadis, P., et al., Insulin expression in human thymus is modulated by INS 
VNTR alleles at the IDDM2 locus. Nat Genet, 1997. 15(3): p. 289-92. 
225. Rioux, J.D. and A.K. Abbas, Paths to understanding the genetic basis of 
autoimmune disease. Nature, 2005. 435(7042): p. 584-9. 
226. Turunen, J.A., et al., Association analysis of the AIRE and insulin genes in 
Finnish type 1 diabetic patients. Immunogenetics, 2006. 58(5-6): p. 331-8. 
227. Andreasson, H., U. Gyllensten, and M. Allen, Real-time DNA quantification of 
nuclear and mitochondrial DNA in forensic analysis. BioTechniques, 2002. 
33(2): p. 402-4, 407-11. 
228. Barrett, J.C., et al., Haploview: analysis and visualization of LD and haplotype 
maps. Bioinformatics, 2005. 21(2): p. 263-5. 
229. Ey, P.L., S.J. Prowse, and C.R. Jenkin, Isolation of pure IgG1, IgG2a and 
IgG2b immunoglobulins from mouse serum using protein A-sepharose. 
Immunochemistry, 1978. 15(7): p. 429-36. 
230. Bilbao, J.R., et al., HLA-DRB1 and MICA in autoimmunity: common 
associated alleles in autoimmune disorders. Annals of the New York 
Academy of Sciences, 2003. 1005: p. 314-8. 
231. Gambelunghe, G., et al., Microsatellite polymorphism of the MHC class I 
chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune 
Addison's disease. The Journal of clinical endocrinology and metabolism, 
1999. 84(10): p. 3701-7. 
232. Myhre, A.G., et al., Autoimmune adrenocortical failure in Norway 
autoantibodies and human leukocyte antigen class II associations related to 
clinical features. The Journal of clinical endocrinology and metabolism, 2002. 
87(2): p. 618-23. 
233. Park, Y.S., et al., Additional association of intra-MHC genes, MICA and 
D6S273, with Addison's disease. Tissue antigens, 2002. 60(2): p. 155-63. 
234. Yu, L., et al., DRB1*04 and DQ alleles: expression of 21-hydroxylase 
autoantibodies and risk of progression to Addison's disease. The Journal of 
clinical endocrinology and metabolism, 1999. 84(1): p. 328-35. 
235. Blomhoff, A., et al., Polymorphisms in the cytotoxic T lymphocyte antigen-4 
gene region confer susceptibility to Addison's disease. The Journal of clinical 
endocrinology and metabolism, 2004. 89(7): p. 3474-6. 
236. Kemp, E.H., et al., A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene 
polymorphism is associated with autoimmune Addison's disease in English 
patients. Clinical endocrinology, 1998. 49(5): p. 609-13. 
237. Vaidya, B., et al., Association analysis of the cytotoxic T lymphocyte antigen-4 
(CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic 
autoimmune Addison's disease. The Journal of clinical endocrinology and 
metabolism, 2000. 85(2): p. 688-91. 
238. Velaga, M.R., et al., The codon 620 tryptophan allele of the lymphoid tyrosine 
phosphatase (LYP) gene is a major determinant of Graves' disease. The 
Journal of clinical endocrinology and metabolism, 2004. 89(11): p. 5862-5. 
 80
239. Soderbergh, A., et al., Autoantibodies against aromatic L-amino acid 
decarboxylase identifies a subgroup of patients with Addison's disease. The 
Journal of clinical endocrinology and metabolism, 2000. 85(1): p. 460-3. 
240. Gregersen, P.K. and L.M. Olsson, Recent advances in the genetics of 
autoimmune disease. Annual review of immunology, 2009. 27: p. 363-91. 
241. Kuroda, N., et al., Development of autoimmunity against transcriptionally 
unrepressed target antigen in the thymus of Aire-deficient mice. Journal of 
immunology, 2005. 174(4): p. 1862-70. 
242. Perniola, R., et al., Immunophenotypic characterisation of peripheral blood 
lymphocytes in autoimmune polyglandular syndrome type 1: clinical study and 
review of the literature. Journal of pediatric endocrinology & metabolism : 
JPEM, 2005. 18(2): p. 155-64. 
243. Ferrera, F., et al., AIRE gene polymorphisms in systemic sclerosis associated 
with autoimmune thyroiditis. Clinical immunology, 2007. 122(1): p. 13-7. 
244. Tazi-Ahnini, R., et al., Role of the autoimmune regulator (AIRE) gene in 
alopecia areata: strong association of a potentially functional AIRE 
polymorphism with alopecia universalis. Tissue antigens, 2002. 60(6): p. 489-
95. 
245. Stolarski, B., et al., Molecular background of polyendocrinopathy-candidiasis-
ectodermal dystrophy syndrome in a Polish population: novel AIRE mutations 
and an estimate of disease prevalence. Clinical genetics, 2006. 70(4): p. 348-
54. 
246. Betterle, C., et al., Assessment of adrenocortical function and autoantibodies 
in a baby born to a mother with autoimmune polyglandular syndrome Type 2. 
Journal of endocrinological investigation, 2004. 27(7): p. 618-21. 
247. Popler, J., et al., Autoimmune polyendocrine syndrome type 1: Utility of 
KCNRG autoantibodies as a marker of active pulmonary disease and 
successful treatment with rituximab. Pediatric pulmonology, 2011. 
248. Bratland, E., et al., T cell responses to steroid cytochrome P450 21-
hydroxylase in patients with autoimmune primary adrenal insufficiency. The 
Journal of clinical endocrinology and metabolism, 2009. 94(12): p. 5117-24. 
249. Rottembourg, D., et al., 21-Hydroxylase epitopes are targeted by CD8 T cells 
in autoimmune Addison's disease. Journal of autoimmunity, 2010. 35(4): p. 
309-15. 
250. Husebye, E.S., et al., Inhibition of aromatic L-amino acid decarboxylase 
activity by human autoantibodies. Clinical and experimental immunology, 
2000. 120(3): p. 420-3. 
251. Nikfarjam, L., et al., Mechanism of inhibition of cytochrome P450 C21 enzyme 
activity by autoantibodies from patients with Addison's disease. European 
journal of endocrinology / European Federation of Endocrine Societies, 2005. 
152(1): p. 95-101. 
252. Bjork, E., et al., GAD autoantibodies in IDDM, stiff-man syndrome, and 
autoimmune polyendocrine syndrome type I recognize different epitopes. 
Diabetes, 1994. 43(1): p. 161-5. 
253. Betterle, C., et al., I. Adrenal cortex and steroid 21-hydroxylase 
autoantibodies in adult patients with organ-specific autoimmune diseases: 
 81
markers of low progression to clinical Addison's disease. The Journal of 
clinical endocrinology and metabolism, 1997. 82(3): p. 932-8. 
254. Betterle, C., et al., II. Adrenal cortex and steroid 21-hydroxylase 
autoantibodies in children with organ-specific autoimmune diseases: markers 
of high progression to clinical Addison's disease. The Journal of clinical 
endocrinology and metabolism, 1997. 82(3): p. 939-42. 
255. Husebye, E.S., Functional autoantibodies cause hypoparathyroidism. The 
Journal of clinical endocrinology and metabolism, 2009. 94(12): p. 4655-7. 
256. Kisand, K., et al., Mucocutaneous candidiasis and autoimmunity against 
cytokines in APECED and thymoma patients: clinical and pathogenetic 
implications. European journal of immunology, 2011. 41(6): p. 1517-27. 
257. Mire-Sluis, A.R., R. Gaines Das, and A. Lernmark, The World Health 
Organization International Collaborative Study for islet cell antibodies. 
Diabetologia, 2000. 43(10): p. 1282-92. 
258. Lernmark, A., Autoimmune diseases: are markers ready for prediction? The 
Journal of clinical investigation, 2001. 108(8): p. 1091-6. 
259. Leslie, D., P. Lipsky, and A.L. Notkins, Autoantibodies as predictors of 
disease. The Journal of clinical investigation, 2001. 108(10): p. 1417-22. 
260. Meager, A., et al., Anti-cytokine autoantibodies in autoimmunity: 
preponderance of neutralizing autoantibodies against interferon-alpha, 
interferon-omega and interleukin-12 in patients with thymoma and/or 
myasthenia gravis. Clinical and experimental immunology, 2003. 132(1): p. 
128-36. 
261. Strobel, P., et al., Deficiency of the autoimmune regulator AIRE in thymomas 
is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-
1). J Pathol, 2007. 211(5): p. 563-71. 
262. Asakawa, H., et al., A patient with thymoma and four different organ-specific 
autoimmune diseases. The Netherlands journal of medicine, 2002. 60(7): p. 
292-5. 
263. Fumeaux, Z., et al., Complete remission of pure white cell aplasia associated 
with thymoma, autoimmune thyroiditis and type 1 diabetes. European journal 
of haematology, 2003. 70(3): p. 186-9. 
264. Evoli, A., et al., Thymoma in patients with MG: characteristics and long-term 
outcome. Neurology, 2002. 59(12): p. 1844-50. 
265. Guerau-de-Arellano, M., et al., Neonatal tolerance revisited: a perinatal 
window for Aire control of autoimmunity. J Exp Med, 2009. 206(6): p. 1245-
52. 
266. Freeman, A.F. and S.M. Holland, Clinical manifestations, etiology, and 
pathogenesis of the hyper-IgE syndromes. Pediatric research, 2009. 65(5 Pt 2): 
p. 32R-37R. 
267. Mangan, P.R., et al., Transforming growth factor-beta induces development of 
the T(H)17 lineage. Nature, 2006. 441(7090): p. 231-4. 
268. Veldhoen, M., et al., TGFbeta in the context of an inflammatory cytokine 
milieu supports de novo differentiation of IL-17-producing T cells. Immunity, 
2006. 24(2): p. 179-89. 
 82
269. Luther, C., et al., Decreased frequency of intrathymic regulatory T cells in 
patients with myasthenia-associated thymoma. Journal of neuroimmunology, 
2005. 164(1-2): p. 124-8. 
270. Evoli, A., et al., Paraneoplastic diseases associated with thymoma. Journal of 
neurology, 2007. 254(6): p. 756-62. 
271. Fattorossi, A., et al., Thymopoiesis, regulatory T cells, and TCRVbeta 
expression in thymoma with and without myasthenia gravis, and modulatory 
effects of steroid therapy. Journal of clinical immunology, 2008. 28(2): p. 194-
206. 
272. Strobel, P., et al., Selective loss of regulatory T cells in thymomas. Annals of 
neurology, 2004. 56(6): p. 901-4. 
273. Lindh, E., et al., AIRE deficiency leads to impaired iNKT cell development. 
Journal of autoimmunity, 2010. 34(1): p. 66-72. 
274. Perniola, R., et al., Innate and adaptive immunity in patients with autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy. Mycoses, 2008. 51(3): 
p. 228-35. 
275. Passlick, B., D. Flieger, and H.W. Ziegler-Heitbrock, Identification and 
characterization of a novel monocyte subpopulation in human peripheral 
blood. Blood, 1989. 74(7): p. 2527-34. 
276. Dayyani, F., et al., Mechanism of glucocorticoid-induced depletion of human 
CD14+CD16+ monocytes. Journal of leukocyte biology, 2003. 74(1): p. 33-9. 
277. Fingerle-Rowson, G., et al., Selective depletion of CD14+ CD16+ monocytes 
by glucocorticoid therapy. Clinical and experimental immunology, 1998. 
112(3): p. 501-6. 
 
 
 
 
